

# CITATION REPORT

List of articles citing

**Pharmacokinetics of pegylated liposomal Doxorubicin:  
review of animal and human studies**

**DOI: 10.2165/00003088-200342050-00002**  
**Clinical Pharmacokinetics, 2003, 42, 419-36.**

**Source:** <https://exaly.com/paper-pdf/35378175/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1209	Rational design and engineering of delivery systems for therapeutics: biomedical exercises in colloid and surface science. <b>2003</b> , 106, 147-68		98
1208	Developments in drug delivery: implications for cancer care. <b>2003</b> , 15, 293-9		10
1207	Direct <sup>99m</sup> Tc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. <b>2004</b> , 308, 419-25		109
1206	Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. <b>2004</b> , 78, 2863-74		109
1205	Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. <b>2004</b> , 6, 343-53		181
1204	Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. <b>2004</b> , 64, 547-53		126
1203	Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx <sup>TM</sup> ) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. <b>2004</b> , 15, 1566-73		16
1202	The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. <b>2004</b> , 32, 794-9		70
1201	Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats. <b>2004</b> , 90, 1830-2		5
1200	Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days. <b>2004</b> , 311, 874-84		57
1199	Advantages of liposomal delivery systems for anthracyclines. <b>2004</b> , 31, 5-15		168
1198	Cardiac safety of liposomal anthracyclines. <b>2004</b> , 31, 161-81		131
1197	Biodistribution of filamentous phage peptide libraries in mice. <b>2004</b> , 31, 121-9		60
1196	Drug delivery systems: entering the mainstream. <b>2004</b> , 303, 1818-22		3515
1195	Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. <b>2004</b> , 53, 452-7		45
1194	Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. <b>2004</b> , 56, 185-229		2619
1193	Biodegradable PEGylated microspheres and nanospheres. <b>2004</b> , 2, 157-171		14

1192	Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck. <b>2004</b> , 40, 1517-21	8
1191	Drug interactions in oncology. <b>2004</b> , 5, 489-96	205
1190	PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy. <b>2004</b> , 27, 443-4	32
1189	A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. <b>2004</b> , 95, 381-9	49
1188	Pegylated liposomal doxorubicin as a chemotherapeutic agent for treatment of canine transmissible venereal tumor in murine models. <b>2005</b> , 67, 1133-9	9
1187	Case Study. <b>2005</b> , 427-480	3
1186	In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. <b>2005</b> , 28, 822-8	59
1185	Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity. <b>2005</b> , 249, 2845-2853	260
1184	Folate receptor-mediated drug targeting: from therapeutics to diagnostics. <b>2005</b> , 94, 2135-46	498
1183	A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. <b>2005</b> , 22, 362-72	215
1182	Targeted for drug delivery. <b>2005</b> , 8, 18-26	111
1181	Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). <b>2005</b> , 9, 127-32	27
1180	Circulation kinetics and organ distribution of Hb-vesicles developed as a red blood cell substitute. <b>2005</b> , 312, 702-9	63
1179	Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. <b>2005</b> , 11, 3567-73	116
1178	Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. <b>2005</b> , 16, 300-6	22
1177	Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue. <b>2005</b> , 48, 7305-14	34
1176	Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. <b>2005</b> , 44, 68-97	476
1175	Intelligent hydrogels for the oral delivery of chemotherapeutics. <b>2005</b> , 2, 1003-13	35

1174	Drug transport to brain with targeted liposomes. <b>2005</b> , 2, 99-107	164
1173	Nanomedicine: current status and future prospects. <b>2005</b> , 19, 311-30	1492
1172	Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers. <b>2005</b> , 21, 2560-8	61
1171	Barriers to Gene Delivery Using Synthetic Vectors. <b>2005</b> , 53PA, 19-46	50
1170	Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. <b>2005</b> , 11, 6944-9	362
1169	Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. <b>2006</b> , 12, 1913-20	80
1168	Nanoparticles: health effects--pros and cons. <b>2006</b> , 114, 1818-25	388
1167	Chapter 1: Lipid Microvesicles: On the Four Decades of Liposome Research. <b>2006</b> , 1-48	3
1166	Carrier-mediated delivery of peptidic drugs for cancer therapy. <b>2006</b> , 27, 3020-8	32
1165	Topoisomerase II inhibitors. <b>2006</b> , 1, 3-15	22
1164	Passive Targeting of Solid Tumors. <b>2006</b> , 11-18	1
1163	Applications of Liposomal Drug Delivery Systems to Cancer Therapy. <b>2006</b> , 595-611	3
1162	Targeting and Intracellular Delivery of Drugs. <b>2006</b> ,	5
1161	Amphipathic Weak Base Loading into Preformed Liposomes Having a Transmembrane Ammonium Ion Gradient. <b>2006</b> , 1-25	6
1160	Complete remission of a case of classical Kaposi's sarcoma with liposomal doxorubicin and radiotherapy. <b>2006</b> , 20, 901-2	2
1159	The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. <b>2006</b> , 94, 1615-20	57
1158	Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection. <b>2006</b> , 316, 162-9	63
1157	Encapsulation of doxorubicin in liposomes containing phosphatidylethanol. Part III: Effect on the toxicity and accumulation of antibiotic in myocardium. <b>2006</b> , 40, 155-157	1

1156	Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies. <b>2006</b> , 24, 413-21	5
1155	Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. <b>2006</b> , 57, 34-9	61
1154	The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. <b>2006</b> , 23, 171-84	237
1153	Convection-enhanced delivery of liposomal doxorubicin in intracranial brain tumor xenografts. <b>2006</b> , 1, 79-85	9
1152	Doxorubicin encapsulation and diffusional release from stable, polymeric, hydrogel nanoparticles. <b>2006</b> , 29, 120-9	165
1151	Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m <sup>2</sup> every 4 weeks in previously treated patients with metastatic breast cancer. <b>2006</b> , 70, 141-6	41
1150	Nano-fabricated Materials in Cancer Treatment and Agri-biotech Applications: Buckyballs in Quantum Holy Grails. <b>2006</b> , 52, 339-356	7
1149	Anthracyclines as effective anticancer drugs. <b>2006</b> , 1, 549-68	40
1148	Liposomal delivery as a mechanism to enhance synergism between anticancer drugs. <b>2006</b> , 5, 1639-40	18
1147	A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation. <b>2006</b> , 12, 6800-7	37
1146	Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. <b>2006</b> , 13, 328-37	200
1145	Dextran-poly-ε-caprolactone micro- and nanoparticles: preparation, characterization and tamoxifen solubilization. <b>2006</b> , 16, 307-313	11
1144	Recent Advances in Star Polymer Design: Degradability and the Potential for Drug Delivery. <b>2007</b> , 60, 699	94
1143	Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. <b>2007</b> , 9, 20-8	56
1142	Tumor priming enhances delivery and efficacy of nanomedicines. <b>2007</b> , 322, 80-8	115
1141	Nanoparticulate Systems for Central Nervous System Drug Delivery. <b>2007</b> , 271-280	
1140	Liposomal doxorubicin in breast cancer. <b>2007</b> , 3, 557-69	5
1139	Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. <b>2007</b> , 18, 1081-91	24

1138	Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. <b>2007</b> , 34, 415-23	65
1137	International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. <b>2007</b> , 43, 14-34	198
1136	A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. <b>2007</b> , 65, 259-69	858
1135	Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. <b>2007</b> , 353, 553-8	93
1134	Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. <b>2007</b> , 14, 201-8	37
1133	A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma. <b>2007</b> , 48, 1755-63	0
1132	Oral Abstracts. <b>2007</b> , 20, 210-222	
1131	Targeted nanoparticle-based drug delivery and diagnosis. <b>2007</b> , 15, 163-83	159
1130	Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. <b>2007</b> , 18, 716-21	61
1129	Surface-active liposomes for targeted cancer therapy. <b>2007</b> , 2, 711-24	51
1128	Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. <b>2007</b> , 23, 4019-25	188
1127	Technetium-99m-labeled stealth pH-sensitive liposomes: a new strategy to identify infection in experimental model. <b>2007</b> , 50, 199-207	9
1126	Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone). <b>2007</b> , 25, 132-9	4
1125	Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. <b>2007</b> , 81, 161-70	58
1124	Role of nanotechnology in pharmaceutical product development. <b>2007</b> , 96, 2547-65	145
1123	Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo. <b>2007</b> , 28, 2655-66	62
1122	The effect of oil components on the physicochemical properties and drug delivery of emulsions: tocol emulsion versus lipid emulsion. <b>2007</b> , 335, 193-202	57
1121	Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. <b>2007</b> , 32, 1054-1082	186

1120	Targeted nanoparticles for cancer therapy. <b>2007</b> , 2, 14-21	373
1119	Shape effects of filaments versus spherical particles in flow and drug delivery. <b>2007</b> , 2, 249-55	2056
1118	Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. <b>2007</b> , 17, 739-63	38
1117	Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. <b>2007</b> , 106, 375-80	8
1116	Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?. <b>2007</b> , 118, 204-15	92
1115	[Liposomal formulation of a methotrexate diglyceride conjugate: activity in methotrexate-resistant leukemia cultured cells]. <b>2007</b> , 33, 470-3	1
1114	DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. <b>2007</b> , 16, 855-66	121
1113	A diglyceride derivative of methotrexate: Synthesis and cytotoxic activity in addressed liposomes. <b>2007</b> , 41, 297-301	4
1112	Novel liposomal formulation for targeted gene delivery. <b>2007</b> , 24, 981-90	43
1111	Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil. <b>2008</b> , 25, 1948-55	30
1110	An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. <b>2008</b> , 61, 695-702	93
1109	Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH. <b>2008</b> , 97, 433-54	24
1108	Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. <b>2008</b> , 97, 4696-740	203
1107	Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. <b>2008</b> , 123, 1269-77	78
1106	Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. <b>2008</b> , 58, 119-29	86
1105	Improved HPLC method for doxorubicin quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulations. <b>2008</b> , 22, 1252-8	33
1104	L-histidine-based pH-sensitive anticancer drug carrier micelle: reconstitution and brief evaluation of its systemic toxicity. <b>2008</b> , 358, 177-83	56
1103	Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation. <b>2008</b> , 15, 313-21	50

1102	Liposomes as nanocarriers of lipid-conjugated antitumor drugs melphalan and methotrexate. <b>2008</b> , 3, 228-239	12
1101	Elimination of liposomes by different separation principles used in low-density lipoprotein apheresis. <b>2008</b> , 12, 2-12	14
1100	Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. <b>2008</b> , 222, 299-315	35
1099	Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. <i>Clinical Pharmacokinetics</i> , <b>2008</b> , 47, 619-34	6.2 63
1098	Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. <b>2008</b> , 68, 2535-51	37
1097	Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. <b>2008</b> , 8, 21-32	140
1096	The use of chitosan formulations in cancer therapy. <b>2008</b> , 25, 275-9	58
1095	Follicular dendritic cell sarcoma of the neck: report of a case treated by surgical excision and COP plus (PEG)-liposomal doxorubicin. <b>2008</b> , 27, 33	15
1094	Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. <b>2008</b> , 19, 2321-31	111
1093	Physicochemical and biological characterization of ceramide-containing liposomes: paving the way to ceramide therapeutic application. <b>2008</b> , 24, 6965-80	32
1092	Drug nanoparticles: formulating poorly water-soluble compounds. <b>2008</b> , 36, 43-8	430
1091	Immunogenicity of anthracyclines: moving towards more personalized medicine. <b>2008</b> , 14, 141-51	91
1090	Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model. <b>2008</b> , 35, 883-93	39
1089	Topoisomerase II inhibitors. <b>2008</b> , 3, 13-26	90
1088	New frontiers in nanotechnology for cancer treatment. <b>2008</b> , 26, 74-85	233
1087	Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. <b>2008</b> , 70, 657-65	32
1086	Using PEGylated nano-liposomes to target tissue invaded by a foreign body. <b>2008</b> , 16, 591-5	16
1085	A novel method to label preformed liposomes with <sup>64</sup> Cu for positron emission tomography (PET) imaging. <b>2008</b> , 19, 2577-84	100

1084	Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases. <b>2008</b> , 19, 1274-82	51
1083	Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. <b>2008</b> , 8, 331-42	19
1082	Invisibility of tissues and the mother/fetus paradox: an hypothesis. <b>2008</b> , 18, 91-3	1
1081	Physiological Targeting to Improve Anticancer Drug Selectivity. <b>2008</b> , 61, 647	21
1080	Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. <b>2008</b> , 3, 247-65	66
1079	Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. <b>2008</b> , 5, 205-19	29
1078	MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors. <b>2008</b> , 43, 877-92	35
1077	Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts. <b>2008</b> , 19, 991-8	10
1076	Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. <b>2008</b> , 19, 1-7	33
1075	Radionuclide carriers for targeting of cancer. <b>2008</b> , 3, 181-99	69
1074	Pegylated liposomal doxorubicin in ovarian cancer. <b>2009</b> , 5, 639-50	16
1073	Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. <b>2009</b> , 50, 2073-81	42
1072	Numerical Study of Thermally Targeted Liposomal Drug Delivery in Tumor. <b>2009</b> , 131,	25
1071	Antigen presentation on artificial acellular substrates: modular systems for flexible, adaptable immunotherapy. <b>2009</b> , 9, 451-64	48
1070	New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging. <b>2009</b> , 4, e7628	85
1069	In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. <b>2009</b> , 133, 4-10	77
1068	Pharmacokinetics of single and repeated injection of hemoglobin-vesicles in hemorrhagic shock rat model. <b>2009</b> , 136, 232-9	32
1067	Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. <b>2009</b> , 84, 142-9	37

1066	Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy. <b>2009</b> , 121, 7804-7808	31
1065	Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. <b>2009</b> , 48, 7668-72	424
1064	Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. <b>2009</b> , 379, 174-80	72
1063	Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. <b>2009</b> , 26, 382-94	122
1062	Crucial functionalizations of carbon nanotubes for improved drug delivery: a valuable option?. <b>2009</b> , 26, 746-69	138
1061	Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumors. <b>2009</b> , 26, 1093-100	32
1060	Radioactive liposomes. <b>2009</b> , 1, 69-83	83
1059	Molecular interactions in reverse hexagonal mesophase in the presence of Cyclosporin A. <b>2009</b> , 367, 115-26	37
1058	Nanotechnology for delivery of drugs to the brain for epilepsy. <b>2009</b> , 6, 323-36	90
1057	Simple and precise detection of lipid compounds present within liposomal formulations using a charged aerosol detector. <b>2009</b> , 1216, 781-6	36
1056	Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. <b>2009</b> , 4, 105-18	146
1055	Polymeric Carriers for Anticancer Drugs. <b>2009</b> , 207-243	
1054	[The influence of carbohydrate ligands on the cytotoxicity of liposomes bearing a methotrexate-diglyceride conjugate in human acute leukemia cell cultures]. <b>2009</b> , 35, 542-9	1
1053	Structural rearrangements and interaction within H(II) mesophase induced by cosolubilization of vitamin E and ascorbic acid. <b>2009</b> , 25, 13106-13	20
1052	Concentration- and temperature-induced effects of incorporated desmopressin on the properties of reverse hexagonal mesophase. <b>2009</b> , 113, 6336-46	34
1051	Selection and characterization of small molecules that bind the HIV-1 frameshift site RNA. <b>2009</b> , 4, 844-54	30
1050	[(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. <b>2009</b> , 36, 515-24	96
1049	Controlled application and scheduled removal of nanoparticle based chemotherapeutics (CARL) will reduce dose limiting adverse events in anticancer chemotherapy. <b>2009</b> , 72, 393-7	12

1048	Tumor-Targeted Macromolecular Drug Delivery Based on the Enhanced Permeability and Retention Effect in Solid Tumor. <b>2009</b> , 93-120	11
1047	Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. <b>2009</b> , 6, 1041-51	366
1046	Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. <b>2009</b> , 6, 246-54	47
1045	Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. <b>2009</b> , 19, 5737	208
1044	Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs. <b>2009</b> , 52, 3408-15	66
1043	Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. <b>2009</b> , 6, 1190-204	122
1042	Evaluation of pharmacokinetics of <sup>111</sup> In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model. <b>2009</b> , 24, 453-60	33
1041	Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. <b>2009</b> , 19, 85-90	81
1040	Polymeric nanomedicine for cancer MR imaging and drug delivery. <b>2009</b> , 3497-510	149
1039	Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. <b>2009</b> , 15, 1973-80	140
1038	Thermosensitive liposomes for the delivery of cancer therapeutics. <b>2010</b> , 1, 707-11	13
1037	Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase. <b>2010</b> , 60, 1651-1657	29
1036	Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. <b>2010</b> , 66, 43-52	92
1035	Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?. <b>2010</b> , 66, 1173-84	39
1034	Can anthracycline therapy for pediatric malignancies be less cardiotoxic?. <b>2010</b> , 12, 411-9	33
1033	Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. <b>2010</b> , 143, 274-9	175
1032	Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. <b>2010</b> , 144, 144-50	102
1031	Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. <b>2010</b> , 148, 359-67	158

1030	Biomaterial-based technologies for brain anti-cancer therapeutics and imaging. <b>2010</b> , 1806, 96-107	29
1029	Nanotechnology and human health: risks and benefits. <b>2010</b> , 30, 730-44	106
1028	Controlled application and removal of liposomal therapeutics: effective elimination of pegylated liposomal doxorubicin by double-filtration plasmapheresis in vitro. <b>2010</b> , 25, 54-62	12
1027	Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: in vitro and in vivo. <b>2010</b> , 99, 430-41	26
1026	Influence of stabilizer systems on the properties and phase behavior of supercooled smectic nanoparticles. <b>2010</b> , 350, 229-39	15
1025	Nanoparticles with dextran/chitosan shell and BSA/chitosan core--doxorubicin loading and delivery. <b>2010</b> , 393, 176-84	145
1024	Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. <b>2010</b> , 31, 5564-74	243
1023	The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles. <b>2010</b> , 31, 7386-97	127
1022	Concomitant liposomal doxorubicin and daily palliative radiotherapy in advanced feline soft tissue sarcomas. <b>2010</b> , 51, 349-55	19
1021	Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. <b>2010</b> , 2010, 723798	27
1020	The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia. <b>2010</b> , 5, 581-91	13
1019	Pegylated liposomal doxorubicin in the management of ovarian cancer. <b>2010</b> , 6, 463-83	27
1018	Liposomes targeting tumour stromal cells. <b>2010</b> , 27, 328-40	5
1017	Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. <b>2010</b> , 26, 485-98	119
1016	Effect of pazopanib on tumor microenvironment and liposome delivery. <b>2010</b> , 9, 1798-808	92
1015	Combination radiofrequency ablation and intravenous radiolabeled liposomal Doxorubicin: imaging and quantification of increased drug delivery to tumors. <b>2010</b> , 255, 405-14	40
1014	Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. <b>2010</b> , 7, 187-201	13
1013	Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. <b>2010</b> , 2010,	68

1012	Targeted drug delivery across the blood-brain barrier using ultrasound technique. <b>2010</b> , 1, 819-48	48
1011	Current trends in liposome research. <b>2010</b> , 605, 1-27	74
1010	Nanotechnology in Drug Delivery. <b>2010</b> , 469-492	1
1009	Effect of altered temperature storage on the in vitro cellular uptake of liposome drug products. <b>2010</b> , 20, 178-82	1
1008	Liposomal Cu-64 labeling method using bifunctional chelators: poly(ethylene glycol) spacer and chelator effects. <b>2010</b> , 21, 1206-15	39
1007	Noncovalent liposome linkage and miniaturization of capsosomes for drug delivery. <b>2010</b> , 11, 3548-55	58
1006	Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. <b>2010</b> , 31, 184-93	285
1005	Targeting nanoparticles to cancer. <b>2010</b> , 62, 90-9	654
1004	Enhanced uptake of porous silica microparticles by bifunctional surface modification with a targeting antibody and a biocompatible polymer. <b>2010</b> , 2, 2489-95	34
1003	Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. <b>2010</b> , 31, 2388-98	110
1002	The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. <b>2010</b> , 5, 1415-33	128
1001	Enzyme-triggered nanomedicine: drug release strategies in cancer therapy. <b>2010</b> , 27, 353-63	141
1000	Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy. <b>2010</b> , 678, 124-32	14
999	Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. <b>2010</b> , 7, 1959-73	248
998	Zoledronic acid: an unending tale for an antiresorptive agent. <b>2010</b> , 11, 141-54	42
997	Role of chemotherapy in the management of soft tissue sarcomas. <b>2010</b> , 10, 249-60	52
996	Thermally sensitive dual fluorescent polymeric micelles for probing cell properties. <b>2011</b> , 7, 11211	13
995	Chemoradionuclide therapy with <sup>186</sup> re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response. <b>2011</b> , 26, 603-14	17

994	Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer. <b>2011</b> , 19, 859-73	8
993	Nanotechnology and drug delivery: an update in oncology. <b>2011</b> , 3, 171-85	11
992	Nanoparticle PEGylation for imaging and therapy. <b>2011</b> , 6, 715-28	1433
991	Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells. <b>2011</b> , 43, 362-73	17
990	Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model. <b>2011</b> , 8, 1140-51	73
989	Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice. <b>2011</b> , 19, 701-8	23
988	Molecular-targeted nanotherapies in cancer: enabling treatment specificity. <b>2011</b> , 5, 492-503	38
987	Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. <b>2011</b> , 71, 2531-58	162
986	Cell-mediated drug delivery. <b>2011</b> , 8, 415-33	221
985	Formation of kinetically trapped nanoscopic unilamellar vesicles from metastable nanodiscs. <b>2011</b> , 27, 14308-16	32
984	A novel class of photo-triggerable liposomes containing DPPC:DC(8,9)PC as vehicles for delivery of doxorubicin to cells. <b>2011</b> , 1808, 117-26	97
983	Quantum dot-folic acid conjugates as potential photosensitizers in photodynamic therapy of cancer. <b>2011</b> , 10, 842-51	50
982	Direct, simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE-SPE-HPLC. <b>2011</b> , 879, 3620-5	34
981	A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that mediate high accumulation and reporter gene activity in tumor tissue. <b>2011</b> , 1, 49-56	11
980	In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. <b>2011</b> , 3, 333-44	87
979	Targeting of nanoparticles in cancer: drug delivery and diagnostics. <b>2011</b> , 22, 949-62	88
978	Tryptanthrin-loaded nanoparticles for delivery into cultured human breast cancer cells, MCF7: the effects of solid lipid/liquid lipid ratios in the inner core. <b>2011</b> , 59, 266-71	44
977	A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma. <b>2011</b> , 9, 283-9	26

976	Positron emission tomography imaging of the stability of Cu-64 labeled dipalmitoyl and distearoyl lipids in liposomes. <b>2011</b> , 151, 28-34	29
975	Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. <b>2011</b> , 152, 303-9	131
974	Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). <b>2011</b> , 153, 187-94	68
973	Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. <b>2011</b> , 154, 290-7	114
972	A novel nested liposome drug delivery vehicle capable of ultrasound triggered release of its payload. <b>2011</b> , 155, 358-66	64
971	The therapeutic equivalence of complex drugs. <b>2011</b> , 59, 176-83	69
970	Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin. <b>2011</b> , 43, 318-24	18
969	Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells. <b>2011</b> , 22, 2474-86	80
968	Liposome formulations of combretastatin A4 and its 4-arylcoumarin analogue prodrugs: The antitumor effect in the mouse model of breast cancer. <b>2011</b> , 5, 276-283	2
967	Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability. <b>2011</b> , 13, 585-97	52
966	Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. <b>2011</b> , 63, 161-9	442
965	Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. <b>2011</b> , 63, 427-40	429
964	Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer. <b>2011</b> , 29, 963-70	13
963	Allometric scaling of pegylated liposomal anticancer drugs. <b>2011</b> , 38, 653-69	28
962	Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis. <b>2011</b> , 68, 1223-31	24
961	PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. <b>2011</b> , 412, 132-41	104
960	Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial). <b>2011</b> , 11, 337	25
959	Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts. <b>2011</b> , 6, 135	18

958	Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?. <b>2011</b> , 100, 2835-48	20
957	Nanomaterials: applications in cancer imaging and therapy. <b>2011</b> , 23, H18-40	729
956	Radiolabeled Nanoplatforms: Imaging Hot Bullets Hitting their Target. <b>2011</b> , 399-429	3
955	Biopolymer, Dendrimer, and Liposome Nanoplatforms for Optical Molecular Imaging. <b>2011</b> , 183-196	
954	Challenges facing colloidal delivery systems: From synthesis to the clinic. <b>2011</b> , 16, 171-181	87
953	Gadolinium-based cancer therapeutic liposomes for chemotherapeutics and diagnostics. <b>2011</b> , 84, 82-7	21
952	The interactions between doxorubicin and amphiphilic and acidic $\beta$ -sheet peptides towards drug delivery hydrogels. <b>2011</b> , 360, 525-31	26
951	Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models. <b>2011</b> , 26, 373-80	11
950	Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model. <b>2011</b> , 261, 813-23	30
949	Preparation and Characterization of Stealth Archaeosomes Based on a Synthetic PEGylated Archaeal Tetraether Lipid. <b>2011</b> , 2011, 396068	23
948	Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. <b>2011</b> , 25, 280-9	50
947	Role of phospholipids in the oral and parenteral delivery of poorly water soluble drugs. <b>2011</b> , 21, 5-16	18
946	Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. <b>2011</b> , 32, 408-14	9
945	Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment. <b>2011</b> , 7, 707-20	11
944	Emerging Technologies of Polymeric Nanoparticles in Cancer Drug Delivery. <b>2011</b> , 2011, 1-10	57
943	Nanostructured Surfaces to Target and Kill Circulating Tumor Cells While Repelling Leukocytes. <b>2012</b> , 2012,	24
942	Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?. <b>2012</b> , 17, 1534-40	19
941	Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?. <b>2012</b> , 17, 1541-6	35

940	Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. <b>2012</b> , 52, 180-94	30
939	Ultrasound mediated delivery of liposomal doxorubicin in prostate tumor tissue. <b>2012</b> ,	3
938	Targeted Nanoparticles in Radiotherapy. <b>2012</b> , 105-128	
937	Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept. <b>2012</b> , 2012, 738432	36
936	Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells. <b>2012</b> , 2012, 832059	45
935	High-resolution CT vascular imaging using blood pool contrast agents. <b>2012</b> , 8, 18-22	17
934	In vivo antitumor effect of liposomes with sialyl Lewis <sup>x</sup> including monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach. <b>2012</b> , 28, 821-8	12
933	Recent advances in drug delivery strategies for treatment of ovarian cancer. <b>2012</b> , 9, 567-83	29
932	Heterobivalent ligands target cell-surface receptor combinations in vivo. <b>2012</b> , 109, 21295-300	52
931	Carbon nanotubes as nanocarriers in medicine. <b>2012</b> , 17, 360-368	82
930	In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymerosomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox <sup>®</sup> <b>2012</b> , 29, 2522-33	29
929	Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. <b>2012</b> , 2, 3-44	629
928	Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity. <b>2012</b> , 64, 372-82	12
927	Thermal targeting of an acid-sensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared with the parent compound in vivo. <b>2012</b> , 11, 1547-56	52
926	Diffusion of 1,2-dimethoxyethane and 1,2-dimethoxypropane through phosphatidylcholine bilayers: a molecular dynamics study. <b>2012</b> , 116, 5141-51	23
925	Different effect of hydrogelation on antifouling and circulation properties of dextran-iron oxide nanoparticles. <b>2012</b> , 9, 539-45	28
924	PET imaging of liposomes labeled with an [ <sup>18</sup> F]-fluorocholesteryl ether probe prepared by automated radiosynthesis. <b>2012</b> , 22, 295-305	12
923	Assembling nanoparticle coatings to improve the drug delivery performance of lipid based colloids. <b>2012</b> , 4, 1220-30	39

922	Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. <b>2012</b> , 30, 4091-7	67
921	Tethered fibronectin liposomes on supported lipid bilayers as a prepackaged controlled-release platform for cell-based assays. <b>2012</b> , 13, 2254-62	12
920	Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. <b>2012</b> , 39, 35-43	29
919	Aptamer-conjugated polymeric nanoparticles for targeted cancer therapy. <b>2012</b> , 2, 418-36	13
918	EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies. <b>2012</b> , 8, 655-64	63
917	Focused ultrasound facilitated thermo-chemotherapy for targeted retinoblastoma treatment: a modeling study. <b>2012</b> , 100, 17-25	9
916	Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancer. <b>2012</b> , 6, 7956-65	80
915	Internalization of paramagnetic phosphatidylserine-containing liposomes by macrophages. <b>2012</b> , 10, 37	24
914	Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. <b>2013</b> , 65, 157-70	1415
913	Drug Delivery Using Nanocarriers: Indian Perspective. <b>2012</b> , 82, 167-206	11
912	Comparative studies of polyethylene glycol-modified liposomes prepared using different PEG-modification methods. <b>2012</b> , 1818, 2801-7	72
911	Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods. <b>2012</b> , 1818, 2901-7	31
910	Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. <b>2012</b> , 22, 177-92	58
909	Novel PLGGE graft polymeric micelles for doxorubicin delivery. <b>2012</b> , 57, 3994-4004	2
908	PEGylated liposomal doxorubicin targeted to $\beta$ -1-expressing MDA-MB-231 breast cancer cells. <b>2012</b> , 28, 4729-36	63
907	Immunoliposomes for Specific Drug Delivery. <b>2012</b> , 229-266	
906	Correlation between radioactivity and chemotherapeutics of the (111)In-VNB-liposome in pharmacokinetics and biodistribution in rats. <b>2012</b> , 7, 683-92	3
905	Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery. <b>2012</b> , 7, 3517-26	54

904	Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent. <b>2012</b> , 7, 2007-17	32
903	Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives. <b>2012</b> , 7, 5423-36	38
902	pH-controlled delivery of doxorubicin to cancer cells, based on small mesoporous carbon nanospheres. <b>2012</b> , 8, 2715-20	151
901	Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. <b>2012</b> , 41, 2971-3010	1286
900	Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species. <b>2012</b> , 101, 3864-76	36
899	Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. <b>2012</b> , 23, 1322-32	127
898	Nanostructure-based drug delivery systems for brain targeting. <b>2012</b> , 38, 387-411	40
897	Synthesis, characterization, and drug delivery of amphiphilic poly{(lactic acid)-co-[(glycolic acid)-alt-(L-glutamic acid)]}-g-poly(ethylene glycol). <b>2012</b> , 20, 250-258	9
896	Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. <b>2012</b> , 69, 1117-26	9
895	Amphiphilic block co-polymers: preparation and application in nanodrug and gene delivery. <b>2012</b> , 8, 2017-33	80
894	Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport. <b>2012</b> , 64, 943-52	60
893	Treating metastatic cancer with nanotechnology. <b>2011</b> , 12, 39-50	880
892	Characterization of the PEG layer of sterically stabilized liposomes: a SAXS study. <b>2012</b> , 165, 387-92	26
891	Novel analytical method to evaluate the surface condition of polyethylene glycol-modified liposomes. <b>2012</b> , 397, 73-79	12
890	In vitro application of paclitaxel loaded magnetoliposomes for combined chemotherapy and hyperthermia. <b>2012</b> , 96, 1-7	76
889	Self-assembled drug delivery systems. Part 6: in vitro/in vivo studies of anticancer N-octadecanoyl gemcitabine nanoassemblies. <b>2012</b> , 430, 276-81	21
888	Designing a novel in vitro drug-release-testing method for liposomes prepared by pH-gradient method. <b>2012</b> , 430, 381-7	12
887	Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. <b>2012</b> , 45, 388-98	83

886	A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. <b>2012</b> , 8, 103-11	132
885	Polyplex-microbubble hybrids for ultrasound-guided plasmid DNA delivery to solid tumors. <b>2012</b> , 157, 224-34	95
884	The journey of a drug-carrier in the body: an anatomo-physiological perspective. <b>2012</b> , 161, 152-63	478
883	Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. <b>2012</b> , 160, 281-9	68
882	Hyaluronan-modified and regular multilamellar liposomes provide sub-cellular targeting to macrophages, without eliciting a pro-inflammatory response. <b>2012</b> , 160, 388-93	34
881	Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer. <b>2012</b> , 160, 274-80	42
880	Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. <b>2012</b> , 160, 245-53	43
879	Quantitative structure-property relationship modeling of remote liposome loading of drugs. <b>2012</b> , 160, 147-57	62
878	Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer. <b>2012</b> , 160, 394-400	89
877	Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. <b>2012</b> , 158, 487-94	212
876	Carbon nanotubes-liposomes conjugate as a platform for drug delivery into cells. <b>2012</b> , 160, 339-45	74
875	E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells. <b>2012</b> , 160, 609-17	64
874	Doxil <sup>®</sup> --the first FDA-approved nano-drug: lessons learned. <b>2012</b> , 160, 117-34	2560
873	A thermosensitive liposome prepared with a Cu <sup>II</sup> gradient demonstrates improved pharmacokinetics, drug delivery and antitumor efficacy. <b>2012</b> , 161, 142-9	65
872	Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. <b>2012</b> , 69, 43-50	77
871	Encapsulation and release of Amphotericin B from an ABC triblock fluoruous copolymer. <b>2012</b> , 29, 69-82	19
870	Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. <b>2013</b> , 33, 457-516	56
869	Cell response to PEGylated poly(dopamine) coated liposomes considering shear stress. <b>2013</b> , 1830, 4838-47	33

868	Preparation, drug release, and cell growth inhibition of a gelatin: doxorubicin conjugate. <b>2013</b> , 30, 2087-96	10
867	Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. <b>2013</b> , 5, 8307-8325	91
866	Paramagnetic liposomes for molecular MRI and MRI-guided drug delivery. <b>2013</b> , 26, 728-44	72
865	Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts. <b>2013</b> , 334, 263-73	57
864	Drug delivery interfaces in the 21st century: from science fiction ideas to viable technologies. <b>2013</b> , 10, 3531-43	68
863	Citric acid- $\beta$ -cyclodextrin crosslinked oligomers as carriers for doxorubicin delivery. <b>2013</b> , 12, 1841-54	47
862	The impact of vaporized nanoemulsions on ultrasound-mediated ablation. <b>2013</b> , 1, 2	22
861	Interaction of liposomes bearing a lipophilic doxorubicin prodrug with tumor cells. <b>2013</b> , 7, 12-20	3
860	Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. <b>2013</b> , 335, 191-200	67
859	Improving intracellular doxorubicin delivery through nanoliposomes equipped with selective tumor cell membrane permeabilizing short-chain sphingolipids. <b>2013</b> , 30, 1883-95	12
858	Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance. <b>2013</b> , 3, 1949	18
857	Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice. <b>2013</b> , 443, 9-16	17
856	Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. <b>2013</b> , 172, 1045-64	176
855	Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan. <b>2013</b> , 443, 17-25	31
854	Polymer-liposome Complexes with a Functional Hydrogen-Bond Cross-Linker for Preventing Protein Adsorption and Improving Tumor Accumulation. <b>2013</b> , 25, 4364-4372	29
853	Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology. <b>2013</b> , 347, 599-606	60
852	Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. <b>2013</b> , 34, 3098-109	81
851	Cell surface receptor targeted biomimetic apatite nanocrystals for cancer therapy. <b>2013</b> , 9, 3834-44	62

850	RADIOLABELED LIPOSOMES AS DRUG DELIVERY NANOTHERANOSTICS. <b>2013</b> , 252-267	4
849	Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. <b>2013</b> , 69, 2073-81	12
848	SPECT/CT imaging of temperature-sensitive liposomes for MR-image guided drug delivery with high intensity focused ultrasound. <b>2013</b> , 169, 82-90	72
847	Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. <b>2013</b> , 172, 782-94	657
846	Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs. <b>2013</b> , 9, 1085-95	1
845	Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity. <b>2013</b> , 19, 865-77	18
844	Passive targeting of lipid-based nanoparticles to mouse cardiac ischemia-reperfusion injury. <b>2013</b> , 8, 117-26	22
843	Biocompatible microemulsion modifies the pharmacokinetic profile and cardiotoxicity of doxorubicin. <b>2013</b> , 102, 289-96	17
842	Nanomedicines and nanodiagnostics come of age. <b>2013</b> , 102, 305-10	36
841	Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin. <b>2013</b> , 334, 284-92	31
840	Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment. <b>2013</b> , 112, 421-8	18
839	Ultrasound improves the uptake and distribution of liposomal Doxorubicin in prostate cancer xenografts. <b>2013</b> , 39, 1255-66	19
838	Lipid-Based Nanoparticles in Cardiovascular Molecular Imaging. <b>2013</b> , 6, 69-75	1
837	Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. <b>2013</b> , 334, 245-52	60
836	Theranostic Nanoparticles for Cancer Imaging and Therapy. <b>2013</b> , 369-393	3
835	Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity. <b>2013</b> , 84, 517-25	63
834	Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. <b>2013</b> , 167, 130-7	138
833	Monitoring pH-triggered drug release from radioluminescent nanocapsules with X-ray excited optical luminescence. <b>2013</b> , 7, 1178-87	97

832	Hyperthermia-induced drug targeting. <b>2013</b> , 10, 511-27	161
831	Cationic thermosensitive liposomes: a novel dual targeted heat-triggered drug delivery approach for endothelial and tumor cells. <b>2013</b> , 13, 2324-31	93
830	Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview. <b>2013</b> , 5, 42-50	44
829	Innovative approaches for demonstration of bioequivalence: the US FDA perspective. <b>2013</b> , 4, 725-40	33
828	Biodegradation of iron oxide nanocubes: high-resolution in situ monitoring. <b>2013</b> , 7, 3939-52	192
827	An evaluation of the anti-tumor efficacy of oleanolic acid-loaded PEGylated liposomes. <b>2013</b> , 24, 235102	22
826	Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. <b>2013</b> , 168, 142-50	165
825	Synthesis of random copolymer based pH-responsive nanoparticles as drug carriers for cancer therapeutics. <b>2013</b> , 4, 3667	14
824	Nanocarriers for the targeted treatment of ovarian cancers. <b>2013</b> , 34, 1073-101	56
823	Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery. <b>2013</b> , 135, 17617-29	483
822	Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts. <b>2013</b> , 52, 200-6	44
821	Nanosopic Agents in a Physiological Environment: The Importance of Understanding Their Characteristics. <b>2013</b> , 29-54	1
820	Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery. <b>2013</b> , 2013, 378380	35
819	Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials. <b>2013</b> , 2013, 1-12	53
818	Lipid-based nanoparticles in cancer diagnosis and therapy. <b>2013</b> , 2013, 165981	48
817	Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. <b>2013</b> , 2013, 898146	38
816	Postinfarct active cardiac-targeted delivery of erythropoietin by liposomes with sialyl Lewis X repairs infarcted myocardium in rabbits. <b>2013</b> , 304, H1124-33	23
815	Targeting Drugs to Cancer: A Tough Journey to the Tumor Cell. <b>2013</b> , 509-542	

814	Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?. <b>2013</b> , 4, 134	26
813	Peptide-based targeting strategies for simultaneous imaging and therapy with nanovectors. <b>2013</b> , 45, 481-493	70
812	Development and characterization of dexamethasone mesylate anchored on multi walled carbon nanotubes. <b>2013</b> , 21, 67-76	48
811	Magnetic-fluid-loaded liposomes for MR imaging and therapy of cancer. <b>2013</b> , 23, 25-37	9
810	Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. <b>2013</b> , 12, 2628-39	29
809	Glucocorticosteroids in nano-sterically stabilized liposomes are efficacious for elimination of the acute symptoms of experimental cerebral malaria. <b>2013</b> , 8, e72722	37
808	Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment. <b>2013</b> , 7, 375-88	124
807	Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology. <b>2014</b> , 6, 137-74	67
806	Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells. <b>2014</b> , 9, 1413-21	46
805	Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer. <b>2014</b> , 9, 4485-94	21
804	A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo. <b>2014</b> , 9, 4581-95	14
803	Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. <b>2014</b> , 25, 206-10	18
802	Pharmacokinetics of liver-targeted docetaxel liposomes modified with 6--acyl-D-galactose esters in rabbits. <b>2014</b> , 2, 545-548	7
801	Drug Formulations: How these Affects Anticancer Drug. <b>2014</b> , 689-701	
800	Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection. <b>2014</b> , 66, 1231-9	18
799	Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: a review. <b>2014</b> , 45, 609-19	57
798	Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. <b>2014</b> , 93, 129-36	18
797	Intertrigo-like dermatitis with pegylated liposomal doxorubicin: diagnosis and management. <b>2014</b> , 32, e104-6	5

796	Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model. <b>2014</b> , 21, 383-94	18
795	Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein. <b>2014</b> , 10, 421-30	38
794	Angiosarcoma of the face and scalp: effective systemic treatment in the older patient. <b>2014</b> , 5, 276-80	18
793	A physiological perspective on the use of imaging to assess the in vivo delivery of therapeutics. <b>2014</b> , 42, 280-98	8
792	Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old. <b>2014</b> , 73, 517-24	10
791	Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. <b>2014</b> , 15, 694-708	118
790	Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. <b>2014</b> , 117, 253-9	18
789	A novel two-step mild hyperthermia for advanced liposomal chemotherapy. <b>2014</b> , 174, 202-8	65
788	Preparation, antitumor activity in mice, pharmacokinetics and tissue distribution in rats of di-n-butyl-di-(4-chlorobenzohydroxamate)tin(IV) liposome. <b>2014</b> , 28, 204-210	4
787	Nanoparticles containing insoluble drug for cancer therapy. <b>2014</b> , 32, 778-88	100
786	Iron-Loaded Magnetic Nanocapsules for pH-Triggered Drug Release and MRI Imaging. <b>2014</b> , 26, 2105-2112	71
785	Nanomedicines: addressing the scientific and regulatory gap. <b>2014</b> , 1313, 35-56	266
784	Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. <b>2014</b> , 190, 556-62	69
783	Theranostic nanomedicine for cancer detection and treatment. <b>2014</b> , 22, 3-17	116
782	Green fabrication of porous chitosan/graphene oxide composite xerogels for drug delivery. <b>2014</b> , 131, n/a-n/a	10
781	Quantitative synchrotron X-ray fluorescence study of the penetration of transferrin-conjugated gold nanoparticles inside model tumour tissues. <b>2014</b> , 6, 9774-82	26
780	A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel. <b>2014</b> , 10, 371-80	31
779	Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. <b>2014</b> , 66, 2-25	1848

778	Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms. <b>2014</b> , 31, 401-13	91
777	Therapeutic efficacy of the combination of doxorubicin-loaded liposomes with inertial cavitation generated by confocal ultrasound in AT2 Dunning rat tumour model. <b>2014</b> , 22, 688-97	17
776	Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns. <b>2014</b> , 10, 1691-702	56
775	Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer. <b>2014</b> , 85, 213	11
774	PEG-stabilized bilayer nanodisks as carriers for doxorubicin delivery. <b>2014</b> , 11, 3279-90	38
773	Ceramics for Drug Delivery. <b>2014</b> , 343-382	1
772	Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes. <b>2014</b> , 195, 37-48	53
771	PEGylated nanomedicines: recent progress and remaining concerns. <b>2014</b> , 11, 139-54	86
770	Morphology control of molecular assemblies prepared from bio-based amphiphilic polymers with a helical hydrophobic unit and application as nanocarriers for contrast agents and/or drug delivery. <b>2014</b> , 46, 783-791	15
769	DNA nanostructure-based imaging probes and drug carriers. <b>2014</b> , 9, 2013-20	22
768	Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. <b>2014</b> , 11, 1250-8	168
767	Effects of liposomal phospholipids and lipid transport-related protein on the intracellular fate of encapsulated doxorubicin. <b>2014</b> , 11, 560-7	1
766	Functionalization and Assembling of Inorganic Nanocontainers for Optical and Biomedical Applications. <b>2014</b> , 281-342	1
765	Host-guest interactions in Fe(III)-trimesate MOF nanoparticles loaded with doxorubicin. <b>2014</b> , 118, 8532-9	94
764	Development of an Anti-Methoxy Poly(ethylene glycol) (mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules. <b>2014</b> , 47, 6880-6888	6
763	A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies. <b>2014</b> , 74, 419-26	4
762	Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous?. <b>2014</b> , 468, 15-25	50
761	Carbohydrate coated, folate functionalized colloidal graphene as a nanocarrier for both hydrophobic and hydrophilic drugs. <b>2014</b> , 6, 2752-8	69

760	Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site- and Sequence-Specific Drug Release. <b>2014</b> , 24, 4753-4761	32
759	Nanomedicine technology: current achievements and new trends. <b>2014</b> , 2, 77-87	27
758	Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. <b>2014</b> , 11, 2659-74	47
757	Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin. <b>2014</b> , 476, 205-12	40
756	Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies. <b>2014</b> , 9, 709-22	64
755	EPR: Evidence and fallacy. <b>2014</b> , 190, 451-64	478
754	Engineered nanoparticles. How brain friendly is this new guest?. <b>2014</b> , 119-120, 20-38	96
753	Optimization on preparation conditions of <i>Rehmannia glutinosa</i> polysaccharide liposome and its immunological activity. <b>2014</b> , 104, 118-26	28
752	pH-responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapy. <b>2014</b> , 35, 5414-5424	81
751	Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect. <b>2014</b> , 460, 165-72	11
750	State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. <b>2014</b> , 187, 133-44	360
749	Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models. <b>2014</b> , 187, 74-82	76
748	The PEGylated liposomal doxorubicin improves the delivery and therapeutic efficiency of 188Re-Liposome by modulating phagocytosis in C26 murine colon carcinoma tumor model. <b>2014</b> , 41, 765-71	10
747	Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. <b>2014</b> , 2, 69	96
746	Medical Applications of Lipid Nanoparticles. <b>2014</b> , 308-333	
745	Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions. <b>2015</b> , 11, 3755-61	47
744	Reinvention of chemotherapy: drug conjugates and nanoparticles. <b>2015</b> , 27, 232-42	12
743	Poly(ornithine-co-arginine-co-glycine-co-aspartic Acid): Preparation via NCA Polymerization and its Potential as a Polymeric Tumor-Penetrating Agent. <b>2015</b> , 15, 829-38	4

742	Retinoic acid liposome-hydrogel: preparation, penetration through mouse skin and induction of F9 mouse teratocarcinoma stem cells differentiation. <b>2015</b> , 51, 541-549	4
741	Gold Nanotheranostics: Proof-of-Concept or Clinical Tool?. <b>2015</b> , 5, 1853-1879	90
740	Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins. <b>2015</b> , 6, 628	14
739	The Use of Anthracyclines for Therapy of CNS Tumors. <b>2015</b> , 15, 721-7	16
738	Cryo Transmission Electron Microscopy of Three Research-Grade Liposomal Formulations of Doxorubicin. <b>2015</b> , 21, 927-928	4
737	Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects. <b>2015</b> , 6, 43698-711	13
736	Acid-Sensitive Peptide-Conjugated Doxorubicin Mediates the Lysosomal Pathway of Apoptosis and Reverses Drug Resistance in Breast Cancer. <b>2015</b> , 12, 2217-28	23
735	Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model. <b>2015</b> , 94, 207-19	10
734	Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes. <b>2015</b> , 9, 6985-95	174
733	Ehrlich tumor inhibition using doxorubicin containing liposomes. <b>2015</b> , 23, 182-7	20
732	Bionanotechnology and the future of glioma. <b>2015</b> , 6, S45-58	18
731	The efficacy and hyperthermic release of doxorubicin from liposomal doxorubicin hydrochloride in rabbit VX2 tumours. <b>2015</b> , 31, 900-8	1
730	The pharmacokinetics of Zr-89 labeled liposomes over extended periods in a murine tumor model. <b>2015</b> , 42, 155-63	29
729	Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. <b>2015</b> , 32, 2428-38	44
728	A versatile and robust microfluidic platform toward high throughput synthesis of homogeneous nanoparticles with tunable properties. <b>2015</b> , 27, 2298-304	157
727	Augmented EPR effect by photo-triggered tumor vascular treatment improved therapeutic efficacy of liposomal paclitaxel in mice bearing tumors with low permeable vasculature. <b>2015</b> , 200, 106-14	37
726	Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. <b>2015</b> , 11, 543-57	164
725	A Versatile Nanotheranostic Agent for Efficient Dual-Mode Imaging Guided Synergistic Chemo-Thermal Tumor Therapy. <b>2015</b> , 25, 2520-2529	125

724	Anti-PEG immunity: emergence, characteristics, and unaddressed questions. <b>2015</b> , 7, 655-77	296
723	Current understanding of synergistic interplay of chitosan nanoparticles and anticancer drugs: merits and challenges. <b>2015</b> , 99, 2055-64	23
722	An overview of nanotoxicity and nanomedicine research: principles, progress and implications for cancer therapy. <b>2015</b> , 3, 7153-7172	89
721	A drug-specific nanocarrier design for efficient anticancer therapy. <b>2015</b> , 6, 7449	112
720	Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. <b>2015</b> , 468, 490-7	62
719	Synthesis and Characterization of Hybrid Polymer/Lipid Expansile Nanoparticles: Imparting Surface Functionality for Targeting and Stability. <b>2015</b> , 16, 1958-66	27
718	Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. <b>2015</b> , 11, 1797-807	20
717	Multifunctional superparamagnetic iron oxide nanoparticles for combined chemotherapy and hyperthermia cancer treatment. <b>2015</b> , 7, 12728-36	159
716	Cholesterol Modified Self-Assemblies and Their Application to Nanomedicine. <b>2015</b> , 16, 1886-914	58
715	Thermosensitive, near-infrared-labeled nanoparticles for topotecan delivery to tumors. <b>2015</b> , 12, 1335-46	24
714	Plasma, blood and liver tissue sample preparation methods for the separate quantification of liposomal-encapsulated prednisolone phosphate and non-encapsulated prednisolone. <b>2015</b> , 25, 46-57	4
713	Development of a liposome formulation for improved biodistribution and tumor accumulation of pentamidine for oncology applications. <b>2015</b> , 488, 154-64	14
712	pH-responsive cocktail drug nanocarriers by encapsulating paclitaxel with doxorubicin modified poly(amino acid). <b>2015</b> , 5, 43148-43154	11
711	Stimulus-responsive hydrogels: Theory, modern advances, and applications. <b>2015</b> , 93, 1-49	592
710	Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment. <b>2015</b> , 47, 77-87	25
709	C8-glycosphingolipids preferentially insert into tumor cell membranes and promote chemotherapeutic drug uptake. <b>2015</b> , 1848, 1656-70	4
708	Biophysical, biopharmaceutical and toxicological significance of biomedical nanoparticles. <b>2015</b> , 5, 47830-47859	4
707	Liposomes as nanomedical devices. <b>2015</b> , 10, 975-99	1142

706	Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. <b>2015</b> , 26, 241-58	100
705	Anticancer activity of galactoxyloglucan polysaccharide-conjugated doxorubicin nanoparticles: Mechanistic insights and interactome analysis. <b>2015</b> , 93, 183-95	14
704	Multi-drug delivery nanocarriers for combination therapy. <b>2015</b> , 6, 1916-1929	67
703	Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier. <b>2015</b> , 217, 293-9	24
702	Human placental cell and tissue uptake of doxorubicin and its liposomal formulations. <b>2015</b> , 239, 108-14	27
701	Quantitative LC-MS determination of liposomal encapsulated prednisolone phosphate and non-encapsulated prednisolone concentrations in murine whole blood and liver tissue. <b>2015</b> , 115, 552-61	6
700	Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. <b>2015</b> , 6, 8692	281
699	Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes. <b>2015</b> , 220, 368-387	28
698	Nuclear Targeting with an Auger Electron Emitter Potentiates the Action of a Widely Used Antineoplastic Drug. <b>2015</b> , 26, 2397-407	35
697	Adsorption of doxorubicin on citrate-capped gold nanoparticles: insights into engineering potent chemotherapeutic delivery systems. <b>2015</b> , 7, 19611-9	49
696	Relationship between Targeting Efficacy of Liposomes and the Dosage of Targeting Antibody Using Surface Plasmon Resonance. <b>2015</b> , 31, 12177-86	7
695	Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies. <b>2015</b> , 219, 295-312	8
694	Drug delivery of Insulin-like growth factor I. <b>2015</b> , 97, 329-37	5
693	Aggregation-Induced-Emissive Molecule Incorporated into Polymeric Nanoparticulate as FRET Donor for Observing Doxorubicin Delivery. <b>2015</b> , 7, 23760-6	38
692	Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. <b>2015</b> , 10, 2963-2971	80
691	Mechanistic model and analysis of doxorubicin release from liposomal formulations. <b>2015</b> , 217, 82-91	34
690	Selected Issues on Regulation of the Circulation of Non-Biological Complex Drugs. <b>2015</b> , 49, 213-219	2
689	Image-driven pharmacokinetics: nanomedicine concentration across space and time. <b>2015</b> , 10, 2861-79	3

688	Poly(2-ethyl-2-oxazoline)-doxorubicin conjugate-based dual endosomal pH-sensitive micelles with enhanced antitumor efficacy. <b>2015</b> , 26, 110-9	40
687	Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma. <b>2015</b> , 11, 67-76	28
686	A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography. <b>2015</b> , 11, 155-65	41
685	Advances and new technologies applied in controlled drug delivery system. <b>2015</b> , 41, 2165-2200	25
684	Nanomicelles based on X-shaped four-armed pegylated distearyl glycerol as long circulating system for doxorubicin delivery. <b>2015</b> , 66, 96-106	13
683	In vivo toxicity of cationic micelles and liposomes. <b>2015</b> , 11, 467-77	218
682	The importance of nanoparticle shape in cancer drug delivery. <b>2015</b> , 12, 129-42	348
681	Adriamycin - efficacy and possible adverse effects. <b>2016</b> , 17, 38-46	2
680	Intracellular calcium is a target of modulation of apoptosis in MCF-7 cells in the presence of IgA adsorbed to polyethylene glycol. <b>2016</b> , 9, 617-26	12
679	Preparation and Characterization of Baicalein-Loaded Nanoliposomes for Antitumor Therapy. <b>2016</b> , 2016, 1-9	6
678	Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment. <b>2016</b> , 11, 5027-5040	29
677	Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo. <b>2016</b> , 11, 1395-412	36
676	Investigation of Particle Accumulation, Chemosensitivity and Thermosensitivity for Effective Solid Tumor Therapy Using Thermosensitive Liposomes and Hyperthermia. <b>2016</b> , 6, 1717-31	29
675	Nanobiomaterials in drug delivery. <b>2016</b> , 1-37	10
674	Recent Developments of Liposomes as Nanocarriers for Theranostic Applications. <b>2016</b> , 6, 1336-52	164
673	Fluorescence Characterization of Gold Modified Liposomes with Antisense N-myc DNA Bound to the Magnetisable Particles with Encapsulated Anticancer Drugs (Doxorubicin, Ellipticine and Etoposide). <b>2016</b> , 16, 290	10
672	Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform - a detailed survey of rHDL particles ranging from biophysical properties to clinical implications. <b>2016</b> , 12, 2161-2179	46
671	Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. <b>2016</b> , 8, 208-22	28

670	Galactoxylglucan-doxorubicin nanoparticles exerts superior cytotoxic effects on cancer cells-A mechanistic and in silico approach. <b>2016</b> , 92, 20-29	5
669	Radionuclide imaging of liposomal drug delivery. <b>2016</b> , 13, 1231-42	22
668	Organometallic Rhenium Complexes Divert Doxorubicin to the Mitochondria. <b>2016</b> , 55, 2792-5	81
667	Nanomaterials for Sustainable Society. <b>2016</b> , 975-993	0
666	New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. <b>2016</b> , 29, 90-106	132
665	Applied Nanotechnology and Nanoscience in Orthopedic Oncology. <b>2016</b> , 39, 280-6	15
664	Steroidal Nanodrugs Based on Pegylated Nanoliposomes Remote Loaded with Amphipathic Weak Acids Steroid Prodrugs as Anti-Inflammatory Agents. <b>2016</b> , 603-632	
663	The Emergence of Nanopharmacy: From Biology to Nanotechnology and Drug Molecules to Nanodrugs. <b>2016</b> , 43-62	1
662	Development and Commercialization of Nanocarrier-Based Drug Products. <b>2016</b> , 697-734	4
661	Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. <b>2016</b> , 68, 701-87	361
660	Ferrocene-Modified Phospholipid: An Innovative Precursor for Redox-Triggered Drug Delivery Vesicles Selective to Cancer Cells. <b>2016</b> , 32, 4169-78	49
659	Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors. <b>2016</b> , 509, 178-187	38
658	Multifunctional drug nanocarriers facilitate more specific entry of therapeutic payload into tumors and control multiple drug resistance in cancer. <b>2016</b> , 203-251	5
657	Graphene-based nanosheets for delivery of chemotherapeutics and biological drugs. <b>2016</b> , 105, 205-227	146
656	Insights into composition/structure/function relationships of Doxil <sup>®</sup> gained from "high-sensitivity" differential scanning calorimetry. <b>2016</b> , 104, 260-70	43
655	Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencing. <b>2016</b> , 97, 122-32	36
654	Chlorin p6-Based Water-Soluble Amino Acid Derivatives as Potent Photosensitizers for Photodynamic Therapy. <b>2016</b> , 59, 4999-5010	38
653	Liposomes in Apoptosis Induction and Cancer Therapy. <b>2016</b> , 231-237	1

652	Significantly enhanced tumor cellular and lysosomal hydroxychloroquine delivery by smart liposomes for optimal autophagy inhibition and improved antitumor efficiency with liposomal doxorubicin. <b>2016</b> , 12, 949-62	48
651	Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model. <b>2016</b> , 7, 201-12	10
650	Ultrasound-triggered drug delivery for cancer treatment using drug delivery systems: From theoretical considerations to practical applications. <b>2016</b> , 241, 144-163	149
649	Mesoporous Iron Oxide Nanoparticles for Magnetically Triggered Release of Doxorubicin and Hyperthermia Treatment. <b>2016</b> , 22, 17020-17028	34
648	Nanomedicines: From Bench to Bedside and Beyond. <b>2016</b> , 18, 1373-1378	94
647	Investigating the passage of tetramethylpyrazine-loaded liposomes across blood-brain barrier models in vitro and ex vivo. <b>2016</b> , 69, 1010-7	8
646	Fabrication and in vitro characterization of gadolinium-based nanoclusters for simultaneous drug delivery and radiation enhancement. <b>2016</b> , 27, 385104	6
645	Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models. <b>2016</b> , 11, 2431-41	137
644	Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains. <b>2016</b> , 12, 2007-2017	9
643	Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis. <b>2016</b> , 36, e73-9	26
642	Towards the Fabrication of Polyelectrolyte-Based Nanocapsules for Bio-Medical Applications. <b>2016</b> , 6, 496-501	6
641	Anticancer nanoparticulate polymer-drug conjugate. <b>2016</b> , 1, 277-296	48
640	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. <b>2016</b> , 111, 577-591	26
639	Exploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal Nanomedicines. <b>2016</b> , 10, 10294-10307	57
638	Liposomal nano-drugs based on amphipathic weak acid steroid prodrugs for treatment of inflammatory diseases. <b>2016</b> , 24, 805-820	7
637	Nanomedicines for renal disease: current status and future applications. <b>2016</b> , 12, 738-753	125
636	Challenges in preclinical to clinical translation for anticancer carrier-mediated agents. <b>2016</b> , 8, 642-53	7
635	Self-Assembled Smart Nanocarriers for Targeted Drug Delivery. <b>2016</b> , 28, 1302-11	161

634	Organometallic Rhenium Complexes Divert Doxorubicin to the Mitochondria. <b>2016</b> , 128, 2842-2845	19
633	Does Thermosensitive Liposomal Vinorelbine Improve End-Point Survival after Percutaneous Radiofrequency Ablation of Liver Tumors in a Mouse Model?. <b>2016</b> , 279, 762-72	13
632	Evaluation of drug penetration with cationic micelles and their penetration mechanism using an in vitro tumor model. <b>2016</b> , 98, 120-30	34
631	Recent advances in the development of nanomaterials for DC-based immunotherapy. <b>2016</b> , 61, 514-523	8
630	Doxorubicin-Functionalized Silica Nanoparticles Incorporated into a Thermoreversible Hydrogel and Intraperitoneally Administered Result in High Prostate Antitumor Activity and Reduced Cardiotoxicity of Doxorubicin. <b>2016</b> , 2, 1190-1199	26
629	In vitro stability and cytotoxicity analysis of liposomes anchored with octylamine-graft-poly (aspartic). <b>2016</b> , 6, 58034-58045	0
628	Liquid chromatography-tandem mass spectrometry evaluation of the pharmacokinetics of a diacid metabolite of norcantharidin loaded in folic acid-targeted liposomes in mice. <b>2016</b> , 119, 76-83	7
627	Sunflower Polymers for Folate-Mediated Drug Delivery. <b>2016</b> , 17, 69-75	48
626	One Step Encapsulation of Small Molecule Drugs in Liposomes via Electrospray-Remote Loading. <b>2016</b> , 13, 92-9	22
625	MRI Monitoring of Tumor-Selective Anticancer Drug Delivery with Stable Thermosensitive Liposomes Triggered by High-Intensity Focused Ultrasound. <b>2016</b> , 13, 1528-39	25
624	Nanoparticle Attachment to Erythrocyte Via the Glycophorin A Targeted ERY1 Ligand Enhances Binding without Impacting Cellular Function. <b>2016</b> , 33, 1191-203	17
623	Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. <b>2016</b> , 116, 2602-63	1422
622	One-step encapsulation of siRNA between lipid-layers of multi-layer polycation liposomes by lipoplex freeze-thawing. <b>2016</b> , 228, 1-8	17
621	Equivalency challenge: Evaluation of Lipodox <sup>®</sup> as the generic equivalent for Doxil <sup>®</sup> in a human ovarian cancer orthotopic mouse model. <b>2016</b> , 141, 357-363	24
620	Intracellular PK/PD Relationships of Free and Liposomal Doxorubicin: Quantitative Analyses and PK/PD Modeling. <b>2016</b> , 13, 1358-65	22
619	Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. <b>2016</b> , 8, 6948-57	132
618	Preparation and Evaluation of Long-Circulating Deoxypodophyllotoxin-Loaded Liposomes Using Poly(Ethylene Glycol)-Distearoylphosphatidylethanolamine. <b>2016</b> , 11, 134-142	6
617	Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. <b>2016</b> , 12, 1279-90	63

616	Investigation of Factors Determining the Enhanced Permeability and Retention Effect in Subcutaneous Xenografts. <b>2016</b> , 57, 601-7	26
615	A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues. <b>2016</b> , 119, 122-9	23
614	Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues. <b>2016</b> , 33, 686-700	19
613	Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. <b>2016</b> , 22, 599-604	19
612	Nanomedicine applied to translational oncology: A future perspective on cancer treatment. <b>2016</b> , 12, 81-103	173
611	PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. <b>2016</b> , 99, 28-51	1814
610	Platelet mimicry: The emperor's new clothes?. <b>2016</b> , 12, 245-8	14
609	Monoolein-based nanocarriers for enhanced folate receptor-mediated RNA delivery to cancer cells. <b>2016</b> , 26, 199-210	10
608	Multifunctional hybrid-carbon nanotubes: new horizon in drug delivery and targeting. <b>2016</b> , 24, 294-308	35
607	Remote loading of doxorubicin into liposomes by transmembrane pH gradient to reduce toxicity toward H9c2 cells. <b>2016</b> , 24, 165-75	35
606	Mass spectrometry in the pharmacokinetic studies of anticancer natural products. <b>2017</b> , 36, 213-251	16
605	Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. <b>2017</b> , 108, 25-38	687
604	Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent. <b>2017</b> , 27, 99-107	9
603	Toxicity, pharmacokinetics, and in vivo efficacy of biotinylated chitosan surface-modified PLGA nanoparticles for tumor therapy. <b>2017</b> , 45, 1-8	15
602	Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. <b>2017</b> , 519, 1-10	32
601	Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization. <b>2017</b> , 29, 1606628	545
600	Enhancing Doxorubicin Delivery toward Tumor by Hydroxyethyl Starch-g-Polylactide Partner Nanocarriers. <b>2017</b> , 9, 10481-10493	31
599	Targeted delivery of docetaxel via Pi-Pi stacking stabilized dendritic polymeric micelles for enhanced therapy of liver cancer. <b>2017</b> , 75, 1042-1048	16

598	Tumor accumulation of liposomal doxorubicin in three murine models: Optimizing delivery efficiency. <b>2017</b> , 13, 1637-1644	15
597	Self-assembled nanocomplex between polymerized phenylboronic acid and doxorubicin for efficient tumor-targeted chemotherapy. <b>2017</b> , 38, 848-858	23
596	Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs. <b>2017</b> , 526, 443-454	14
595	Deformable Discoidal Polymeric Nanoconstructs for the Precise Delivery of Therapeutic and Imaging Agents. <b>2017</b> , 25, 1514-1521	26
594	Selective growth inhibition of cancer cells with doxorubicin-loaded CB[7]-modified iron-oxide nanoparticles. <b>2017</b> , 7, 23827-23834	19
593	Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells. <b>2017</b> , 69, 834-843	8
592	Comparison of Tumor Penetration of Podophyllotoxin-Carboxymethylcellulose Conjugates with Various Chemical Compositions in Tumor Spheroid Culture and In Vivo Solid Tumor. <b>2017</b> , 28, 1505-1518	23
591	Core-shell drug carriers: liposomes, polymersomes, and niosomes. <b>2017</b> , 63-105	9
590	Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells. <b>2017</b> , 34, 1741-1750	12
589	Characterization of 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[Methoxy(polyethylene glycol)-2000] and Its Complex with Doxorubicin Using Nuclear Magnetic Resonance Spectroscopy and Molecular Dynamics. <b>2017</b> , 28, 1777-1790	4
588	Liposomes coated with thiolated chitosan as drug carriers of curcumin. <b>2017</b> , 80, 156-164	82
587	Gadolinium-based nanoscale MRI contrast agents for tumor imaging. <b>2017</b> , 5, 3431-3461	71
586	Mild microwave activated, chemo-thermal combinational tumor therapy based on a targeted, thermal-sensitive and magnetic micelle. <b>2017</b> , 131, 36-46	45
585	ATN-161 Peptide Functionalized Reversibly Cross-Linked Polymersomes Mediate Targeted Doxorubicin Delivery into Melanoma-Bearing C57BL/6 Mice. <b>2017</b> , 14, 2538-2547	34
584	Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review. <b>2017</b> , 86, 316-323	33
583	Polymer Nanomaterials for Drug Delivery Across the Blood Brain Barrier. <b>2017</b> , 847-868	9
582	High performance liquid chromatography analysis of 100-nm liposomal nanoparticles using polymer-coated, silica monolithic columns with aqueous mobile phase. <b>2017</b> , 1484, 34-40	18
581	Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells. <b>2017</b> , 13, 1219-1227	24

580	Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy. <b>2017</b> , 15-54	1
579	Assessing the Benefits of Drug Delivery by Nanocarriers: A Partico/Pharmacokinetic Framework. <b>2017</b> , 64, 2176-2185	8
578	Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. <b>2017</b> , 8, 777	362
577	Heating treatments affect the thermal behaviour of doxorubicin loaded in PEGylated liposomes. <b>2017</b> , 534, 81-88	11
576	Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer. <b>2017</b> , 12, 2519-2532	10
575	Drug delivery by supramolecular design. <b>2017</b> , 46, 6600-6620	366
574	TQ-B3203, a potent proliferation inhibitor derived from camptothecin. <b>2017</b> , 26, 3395-3406	3
573	Two-step polymer- and liposome-enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives. <b>2017</b> , 118, 52-64	19
572	Mitosis-Mediated Intravasation in a Tissue-Engineered Tumor-Microvessel Platform. <b>2017</b> , 77, 6453-6461	17
571	Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems. <b>2017</b> , 1, 27	24
570	Light-switchable systems for remotely controlled drug delivery. <b>2017</b> , 267, 67-79	44
569	Nanoparticles target early-stage breast cancer metastasis in vivo. <b>2017</b> , 28, 43LT01	27
568	HPMA copolymer-phospholipase C and dextrin-phospholipase A2 as model triggers for polymer enzyme liposome therapy (PELT). <b>2017</b> , 25, 818-828	3
567	Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view. <b>2017</b> , 30, 286-293	4
566	Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model. <b>2017</b> , 12, 1751-1765	22
565	Watching the gorilla and questioning delivery dogma. <b>2017</b> , 262, 87-90	21
564	Polyethylene glycol modified ORMOSIL theranostic nanoparticles for triggered doxorubicin release and deep drug delivery into ovarian cancer spheroids. <b>2017</b> , 174, 209-216	12
563	Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin. <b>2017</b> , 34, 2025-2035	4

562	Self-Assembled Vesicle-Carbon Nanotube Conjugate Formation through a Boronate-Diol Covalent Linkage. <b>2017</b> , 23, 15194-15202	4
561	Transport of Liposome Encapsulated Drugs in Voxelized Computational Model of Human Brain Tumors. <b>2017</b> , 16, 634-644	10
560	Degree of Unsaturation and Backbone Orientation of Amphiphilic Macromolecules Influence Local Lipid Properties in Large Unilamellar Vesicles. <b>2017</b> , 33, 14663-14673	5
559	Nano-palladium is a cellular catalyst for in vivo chemistry. <b>2017</b> , 8, 15906	144
558	Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: High loading capacity, increased stability, and improved anticancer efficacy. <b>2017</b> , 141, 161-175	25
557	Efficient Cancer Regression by a Thermosensitive Liposome for Photoacoustic Imaging-Guided Photothermal/Chemo Combinatorial Therapy. <b>2017</b> , 18, 2306-2314	25
556	Cancer nanomedicine: progress, challenges and opportunities. <b>2017</b> , 17, 20-37	2988
555	Tumor-targeted nanomedicines for cancer theranostics. <b>2017</b> , 115, 87-95	139
554	Nanocarriers in cancer clinical practice: a pharmacokinetic issue. <b>2017</b> , 13, 583-599	39
553	Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. <b>2017</b> , 23, 1955-1966	18
552	Current Update of a Carboxymethylcellulose-PEG Conjugate Platform for Delivery of Insoluble Cytotoxic Agents to Tumors. <b>2017</b> , 19, 386-396	11
551	Introduction to Novel Therapeutic Carriers. <b>2017</b> , 1-24	
550	Rapid Analysis of DOXIL Stability and Drug Release from DOXIL by HPLC Using a Glycidyl Methacrylate-Coated Monolithic Column. <b>2017</b> , 65, 945-949	13
549	Liposomal Delivery Systems: Design Optimization and Current Applications. <b>2017</b> , 40, 1-10	182
548	Nanoparticle-Based Photodynamic Therapy: Current Status and Future Application to Improve Outcomes of Cancer Treatment. <b>2017</b> , 65, 637-641	23
547	The impact of receptor recycling on the exocytosis of $\alpha_5\beta_1$ integrin targeted gold nanoparticles. <b>2017</b> , 8, 38618-38630	11
546	Liposomal Formulations in Clinical Use: An Updated Review. <b>2017</b> , 9,	945
545	Multicomponent, Tumor-Homing Chitosan Nanoparticles for Cancer Imaging and Therapy. <b>2017</b> , 18,	35

544	Phosphorylcholine-based stealthy nanocapsules enabling tumor microenvironment-responsive doxorubicin release for tumor suppression. <b>2017</b> , 7, 1192-1203	43
543	Improving chemotherapy drug delivery by nanoprecision tools. <b>2017</b> , 87-128	3
542	Introductory Chapter: Drug Delivery Concepts. <b>2017</b> ,	3
541	Lipid-Based Nanopharmaceuticals in Antimicrobial Therapy. <b>2017</b> , 111-152	5
540	Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. <b>2017</b> , 8, 256-265	135
539	Preparation, characterization and in vitro study of liposomal curcumin powder by cost effective nanofiber weaving technology. <b>2018</b> , 42, 5117-5127	26
538	Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance. <b>2018</b> , 3, 2508-2517	29
537	Supramolecular polymeric chemotherapy based on cucurbit[7]uril-PEG copolymer. <b>2018</b> , 178, 697-705	49
536	Short Drug-Light Intervals Improve Liposomal Chemophototherapy in Mice Bearing MIA PaCa-2 Xenografts. <b>2018</b> , 15, 3682-3689	15
535	Multicellular Tumor Spheroids (MCTS) as a 3D In Vitro Evaluation Tool of Nanoparticles. <b>2018</b> , 14, e1702858	106
534	Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy. <b>2018</b> , 275, 67-77	30
533	Intelligent anticancer drug delivery performances of two poly(N-isopropylacrylamide)-based magnetite nanohydrogels. <b>2018</b> , 44, 1254-1261	14
532	Immunoliposomes in clinical oncology: State of the art and future perspectives. <b>2018</b> , 275, 162-176	44
531	Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer. <b>2018</b> , 25, 517-532	64
530	Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment. <b>2018</b> , 97, e9932	6
529	Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: bridge to transplant. <b>2018</b> , 36, 489-491	3
528	Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma. <b>2018</b> , 12, 1250-1261	60
527	Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?. <b>2018</b> , 23, 487-492	31

526	Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design. <b>2018</b> , 44, 923-933	17
525	Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook. <b>2018</b> , 26, 435-447	21
524	Numerical Study of Transport of Anticancer Drugs in Heterogeneous Vasculature of Human Brain Tumors Using Dynamic Contrast Enhanced-Magnetic Resonance Imaging. <b>2018</b> , 140,	9
523	Synthesis and biological evaluation of new water-soluble photoactive chlorin conjugate for targeted delivery. <b>2018</b> , 144, 740-750	18
522	Current update of a thermosensitive liposomes composed of DPPC and Brij78. <b>2018</b> , 26, 407-419	7
521	Synthesis and characterization of poly(N-isopropyl methacrylamide) core/shell nanogels for controlled release of chemotherapeutics. <b>2018</b> , 340, 58-65	23
520	Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. <b>2018</b> , 9, 6	124
519	Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples. <b>2018</b> , 39, 825-844	48
518	Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer. <b>2018</b> , 35, 95	13
517	Vesicle-based drug carriers. <b>2018</b> , 1-55	4
516	Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world. <b>2018</b> , 97, 1521-1537	149
515	Methotrexate-conjugated mPEGBCL copolymers: a novel approach for dual triggered drug delivery. <b>2018</b> , 42, 5937-5945	28
514	Investigation of the Discriminatory Ability of Pharmacokinetic Metrics for the Bioequivalence Assessment of PEGylated Liposomal Doxorubicin. <b>2018</b> , 35, 106	4
513	Tailor-Made Self-Assemblies from Functionalized Amphiphiles: Diversity and Applications. <b>2018</b> , 34, 10449-10468	
512	Phosphorylcholine-Based Stealthy Nanocapsules Decorating TPGS for Combatting Multi-Drug-Resistant Cancer. <b>2018</b> , 4, 1679-1686	7
511	The Use of Magnetic Resonance Imaging for Non-Invasive Assessment of Venofer <sup>®</sup> Biodistribution in Rats. <b>2018</b> , 35, 88	4
510	The anticancer activity of antisense microRNA (fRNA) in combination with the lectin from <i>Bacillus subtilis</i> B-7025. <b>2018</b> , 70, 732-739	
509	Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines. <b>2018</b> , 7, 1700432	21

508	Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study. <b>2018</b> , 14, 198-203	6
507	Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab. <b>2018</b> , 97, 141-147	10
506	Aptamer micelles targeting fractalkine-expressing cancer cells in vitro and in vivo. <b>2018</b> , 14, 85-96	12
505	Nanomaterials as nanocarriers: a critical assessment why these are multi-chore vanquisher in breast cancer treatment. <b>2018</b> , 46, 899-916	11
504	Effects of barium chloride adsorbed to polyethylene glycol (PEG) microspheres on co-culture of human blood mononuclear cell and breast cancer cell lines (MCF-7). <b>2018</b> , 40, 18-24	3
503	Determination of non-liposomal and liposomal doxorubicin in plasma by LC-MS/MS coupled with an effective solid phase extraction: In comparison with ultrafiltration technique and application to a pharmacokinetic study. <b>2018</b> , 1072, 149-160	26
502	Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action. <b>2018</b> , 269, 171-176	37
501	Development and characterization of docetaxel-loaded lecithin-stabilized micellar drug delivery system (LMDDs) for improving the therapeutic efficacy and reducing systemic toxicity. <b>2018</b> , 123, 9-19	25
500	On the use of liposome controls in studies investigating the clinical potential of extracellular vesicle-based drug delivery systems - A commentary. <b>2018</b> , 269, 10-14	46
499	Naphthoquinones: A continuing source for discovery of therapeutic antineoplastic agents. <b>2018</b> , 91, 681-690	54
498	Evaluation of Flavonoid Derivative and Doxorubicin Effects in Lung Cancer Cells (A549) Using Differential Pulse Voltammetry Method. <b>2018</b> , 8, 637-642	8
497	Design Optimization of Tumor Vasculature-Bound Nanoparticles. <b>2018</b> , 8, 17768	11
496	Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis. <b>2018</b> , 10, 19338-19350	33
495	Predicting drug delivery efficiency into tumor tissues through molecular simulation of transport in complex vascular networks. <b>2018</b> , 292, 221-234	11
494	Long-Circulating Amphiphilic Doxorubicin for Tumor Mitochondria-Specific Targeting. <b>2018</b> , 10, 43482-43492	22
493	Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer. <b>2018</b> , 13, 6961-6986	27
492	Recent Advances of Novel Proteinoids and Proteinoid Nanoparticles and Their Applications in Biomedicine and Industrial Uses. <b>2018</b> , 58, 1277-1285	8
491	Evaluation of Three Morphologically Distinct Virus-Like Particles as Nanocarriers for Convection-Enhanced Drug Delivery to Glioblastoma. <b>2018</b> , 8,	40

490	Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing. <b>2018</b> , 15, 1261-1270	6
489	Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. <b>2018</b> , 291, 11-25	5
488	Nanomedicine in cancer stem cell therapy: from fringe to forefront. <b>2018</b> , 374, 427-438	22
487	Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers. <b>2018</b> , 553, 483-509	39
486	Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics. <b>2018</b> , 9, 4551	126
485	Redox- and pH-Sensitive Glycan (Polysialic Acid) Derivatives and F127 Mixed Micelles for Tumor-Targeted Drug Delivery. <b>2018</b> , 15, 5534-5545	10
484	Modified Poly(T-Butyl Methacrylate) as a Doxorubicin Carrier for Targeted Delivery. <b>2018</b> , 52, 539-544	2
483	Progression-dependent transport heterogeneity of breast cancer liver metastases as a factor in therapeutic resistance. <b>2018</b> , 291, 99-105	8
482	Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. <b>2018</b> , 12, 11041-11061	162
481	In Vivo Quantitative Understanding of PEGylated Liposome's Influence on Brain Delivery of Diphenhydramine. <b>2018</b> , 15, 5493-5500	14
480	Triggered radiosensitizer delivery using thermosensitive liposomes and hyperthermia improves efficacy of radiotherapy: An in vitro proof of concept study. <b>2018</b> , 13, e0204063	10
479	Adaptive Polymersome and Micelle Morphologies in Anticancer Nanomedicine: From Design Rationale to Fabrication and Proof-of-Concept Studies. <b>2018</b> , 1, 1800068	11
478	Membrane Loaded Copper Oleate PEGylated Liposome Combined with Disulfiram for Improving Synergistic Antitumor Effect In Vivo. <b>2018</b> , 35, 147	17
477	Poly (vinyl alcohol) microneedles: Fabrication, characterization, and application for transdermal drug delivery of doxorubicin. <b>2018</b> , 129, 88-103	84
476	Nanoformulations of doxorubicin: how far have we come and where do we go from here?. <b>2018</b> , 29, 332002	17
475	Perspectives on the past, present, and future of cancer nanomedicine. <b>2018</b> , 130, 3-11	149
474	Manganese-52: applications in cell radiolabelling and liposomal nanomedicine PET imaging using oxine (8-hydroxyquinoline) as an ionophore. <b>2018</b> , 47, 9283-9293	32
473	Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells. <b>2018</b> , 5, 1700859	26

472	Characterization of a smart pH-cleavable PEG polymer towards the development of dual pH-sensitive liposomes. <b>2018</b> , 548, 288-296	19
471	Beyond the Blood-Brain Barrier: Facing New Challenges and Prospects of Nanotechnology-Mediated Targeted Delivery to the Brain. <b>2018</b> , 397-437	4
470	Carbon Dots-Cluster-DOX Nanocomposites Fabricated by a Co-Self-Assembly Strategy for Tumor-Targeted Bioimaging and Therapy. <b>2018</b> , 35, 1800190	17
469	Toxicological status of nanoparticles: What we know and what we don't know. <b>2018</b> , 295, 1-12	59
468	Cancer nanomedicine: mechanisms, obstacles and strategies. <b>2018</b> , 13, 1639-1656	27
467	PEGylated Stealth Nanoparticles and liposomes. <b>2018</b> , 1-26	10
466	Targeted Nanotheranostics for Selective Drug Delivery in Cancer. <b>2018</b> , 245-277	4
465	Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. <b>2018</b> , 19, 1027-1039	110
464	Non-viral gene therapy using multifunctional nanoparticles: Status, challenges, and opportunities. <b>2018</b> , 374, 133-152	47
463	Analytical methods for investigating fate of nanoliposomes: A review. <b>2018</b> , 8, 219-225	17
462	Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment. <b>2018</b> , 8,	15
461	HPLC Method Development for Quantification of Doxorubicin in Cell Culture and Placental Perfusion Media. <b>2018</b> , 5,	10
460	Nanotheranostics and Their Potential in the Management of Metastatic Cancer. <b>2018</b> , 199-244	2
459	Near-Infrared Activated Release of Doxorubicin from Plasmon Resonant Liposomes. <b>2018</b> , 2, 295-305	6
458	Networking of Smart Drugs: A Chem-Bioinformatic Approach to Cancer Treatment. <b>2018</b> , 529-555	
457	Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer. <b>2018</b> , 281, 1-10	18
456	Functional Moieties for Intracellular Traffic of Nanomaterials. <b>2018</b> , 399-448	3
455	C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes. <b>2018</b> , 12, 5834-5847	58

454	Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics. <b>2018</b> , 8, 533-548	119
453	Liposomal therapies in oncology: does one size fit all?. <b>2018</b> , 82, 741-755	16
452	Enhanced efficacy and bioavailability of thymoquinone using nanoliposomal dosage form. <b>2018</b> , 47, 445-453	22
451	Preclinical evaluation of thermosensitive poly(N-(2-hydroxypropyl) methacrylamide mono/dilactate)-grafted liposomes for cancer thermochemotherapy. <b>2018</b> , 550, 190-199	6
450	Companion Diagnostic Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines. <b>2018</b> , 8, 2300-2312	31
449	Toxicological study of a new doxorubicin-loaded pH-sensitive liposome: A preclinical approach. <b>2018</b> , 352, 162-169	18
448	Controlled-release nanotherapeutics: State of translation. <b>2018</b> , 284, 39-48	32
447	Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery. <b>2018</b> , 10, 22951-22962	33
446	A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse. <b>2018</b> , 284, 171-178	25
445	Practical aspects in size and morphology characterization of drug-loaded nano-liposomes. <b>2018</b> , 547, 648-655	22
444	Synthesis, characterization and self-assembly investigation of novel PEG-g-PCL copolymers by combination of ROP and click chemistry method as a sustained release formulation for hydrophobic drug. <b>2019</b> , 68, 540-550	4
443	Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin. <b>2019</b> , 71, 1497-1507	19
442	Interplay of protein corona and immune cells controls blood residency of liposomes. <b>2019</b> , 10, 3686	97
441	Development of a stable single-vial liposomal formulation for vincristine. <b>2019</b> , 14, 4461-4474	2
440	Antibody-guided nanomedicines as novel breakthrough therapeutic, diagnostic and theranostic tools. <b>2019</b> , 7, 4000-4016	29
439	Encapsulation of hydrophobic components in dendrimersomes and decoration of their surface with proteins and nucleic acids. <b>2019</b> , 116, 15378-15385	29
438	Integrating nanomedicine into clinical radiotherapy regimens. <b>2019</b> , 144, 35-56	13
437	Understanding the Influence of Nanocarrier-Mediated Brain Delivery on Therapeutic Performance Through Pharmacokinetic-Pharmacodynamic Modeling. <b>2019</b> , 108, 3425-3433	7

436	Nanomedicine and Drug Delivery Systems in Overcoming Resistance to Targeted Therapy. <b>2019</b> , 291-312	
435	Doxorubicin and liposomal doxorubicin induce senescence by enhancing nuclear factor kappa B and mitochondrial membrane potential. <b>2019</b> , 232, 116677	8
434	Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. <b>2020</b> , 116, 970-982	19
433	Biohybrid Nanoparticles to Negotiate with Biological Barriers. <b>2019</b> , 15, e1902333	14
432	Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo. <b>2019</b> , 11,	17
431	CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice. <b>2019</b> , 14, 8073-8094	14
430	Extravasating Neutrophils Open Vascular Barrier and Improve Liposomes Delivery to Tumors. <b>2019</b> , 13, 12599-12612	25
429	Sequentially dynamic polymeric micelles with detachable PEGylation for enhanced chemotherapeutic efficacy. <b>2019</b> , 145, 54-64	9
428	Supramolecular Graphene-Based Systems for Drug Delivery. <b>2019</b> , 443-479	
427	Nanotargeted agents: an emerging therapeutic strategy for breast cancer. <b>2019</b> , 14, 1771-1786	17
426	Liposome-Encapsulated Morphine Affords a Prolonged Analgesia While Facilitating Extinction of Reward and Aversive Memories. <b>2019</b> , 10, 1082	4
425	Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). <b>2019</b> , 11,	14
424	2-APB and CBD-Mediated Targeting of Charged Cytotoxic Compounds Into Tumor Cells Suggests the Involvement of TRPV2 Channels. <b>2019</b> , 10, 1198	14
423	Ferritin drug carrier (FDC) for tumor targeting therapy. <b>2019</b> , 311-312, 288-300	59
422	The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether- $\beta$ -cyclodextrin and sucrose octasulfate. <b>2018</b> , 7, 419-428	12
421	Nanoparticle-based CT visualization of pulmonary vasculature for minimally-invasive thoracic surgery planning. <b>2019</b> , 14, e0209501	3
420	Induction of Cytochrome P450 Involved in the Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomes In Vivo. <b>2019</b> , 47, 364-376	7
419	Targeted-nanoliposomal combretastatin A4 (CA-4) as an efficient antivascular candidate in the metastatic cancer treatment. <b>2019</b> , 234, 14721	11

4 <sup>18</sup>	Promising Recent Strategies with Potential Clinical Translational Value to Combat Antibacterial Resistant Surge. <b>2019</b> , 6,	7
4 <sup>17</sup>	Self-Assembly of Temperature Sensitive Unilamellar Vesicles by a Blend of Block Copolymers in Aqueous Solution. <b>2019</b> , 11,	5
4 <sup>16</sup>	Rapid release from near-infrared polymer loaded liposomes for photothermal and chemo-combined therapy. <b>2019</b> , 43, 2274-2277	0
4 <sup>15</sup>	Magnetic liposome design for drug release systems responsive to super-low frequency alternating current magnetic field (AC MF). <b>2019</b> , 552, 689-700	23
4 <sup>14</sup>	Light sheet fluorescence microscopy versus confocal microscopy: in quest of a suitable tool to assess drug and nanomedicine penetration into multicellular tumor spheroids. <b>2019</b> , 142, 195-203	30
4 <sup>13</sup>	Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring. <b>2019</b> , 96, 219-232	97
4 <sup>12</sup>	Development of Liposomal Gemcitabine with High Drug Loading Capacity. <b>2019</b> , 16, 2858-2871	25
4 <sup>11</sup>	Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs. <b>2019</b> , 306, 138-148	25
4 <sup>10</sup>	Dual-Ligand Modification of PEGylated Liposomes Used for Targeted Doxorubicin Delivery to Enhance Anticancer Efficacy. <b>2019</b> , 20, 188	16
4 <sup>09</sup>	Combination of intratumoural micellar paclitaxel with radiofrequency ablation: efficacy and toxicity in rodents. <b>2019</b> , 29, 6202-6210	4
4 <sup>08</sup>	Tuning the In Vivo Transport of Anticancer Drugs Using Renal-Clearable Gold Nanoparticles. <b>2019</b> , 58, 8479-8483	45
4 <sup>07</sup>	Tuning the In Vivo Transport of Anticancer Drugs Using Renal-Clearable Gold Nanoparticles. <b>2019</b> , 131, 8567	2
4 <sup>06</sup>	Nanomedicine-based formulations containing $\Omega$ polyunsaturated fatty acids: potential application in cardiovascular and neoplastic diseases. <b>2019</b> , 14, 2809-2828	14
4 <sup>05</sup>	Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments. <b>2019</b> , 151-152, 56-71	29
4 <sup>04</sup>	Direct and simultaneous determination of intra-liposomal and external sulfate in liposomal doxorubicin formulations by capillary electrophoresis/inductively coupled plasma-tandem mass spectrometry (CE/ICP-MS/MS). <b>2019</b> , 561, 283-288	6
4 <sup>03</sup>	Current status of nanoscale drug delivery systems for colorectal cancer liver metastasis. <b>2019</b> , 114, 108764	23
4 <sup>02</sup>	Copper complex nanoformulations featuring highly promising therapeutic potential in murine melanoma models. <b>2019</b> , 14, 835-850	24
4 <sup>01</sup>	A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer. <b>2019</b> , 42, 269-274	2

400	Ferrocene-containing amphiphilic polynorbornenes as biocompatible drug carriers. <b>2019</b> , 10, 2527-2539	22
399	A Simple and Easy Method of Monitoring Doxorubicin Release from a Liposomal Drug Formulation in the Serum Using Fluorescence Spectroscopy. <b>2019</b> , 67, 367-371	3
398	Penetration and Uptake of Nanoparticles in 3D Tumor Spheroids. <b>2019</b> , 30, 1371-1384	85
397	Doxorubicin-loaded red blood cells reduced cardiac toxicity and preserved anticancer activity. <b>2019</b> , 26, 433-442	13
396	Mathematical modeling in cancer nanomedicine: a review. <b>2019</b> , 21, 40	75
395	Nanoparticle Therapy for Vascular Diseases. <b>2019</b> , 39, 635-646	55
394	A Highly Efficient Tumor-Targeting Nanoprobe with a Novel Cell Membrane Permeability Mechanism. <b>2019</b> , 31, e1807456	23
393	cRGD target liposome delivery system promoted immunogenic cell death through enhanced anticancer potency of a thymidine conjugate under UVA activation as a cancer vaccine. <b>2019</b> , 167, 499-509	8
392	Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug. <b>2019</b> , 560, 246-260	10
391	Chitosan nanopolymers: An overview of drug delivery against cancer. <b>2019</b> , 130, 727-736	111
390	Aptamer-functionalized liposomes for targeted cancer therapy. <b>2019</b> , 448, 144-154	68
389	Long-term monitoring in a microfluidic system to study tumour spheroid response to chronic and cycling hypoxia. <b>2019</b> , 9, 17782	19
388	Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery. <b>2019</b> , 9, 8091-8108	36
387	Pegylated liposomal doxorubicin for myeloid neoplasms. <b>2019</b> , 30, 948-952	1
386	Nanotargeted radiopharmaceuticals for cancer diagnosis and treatment. <b>2019</b> , 247-266	
385	Thermosensitive Liposome-Mediated Drug Delivery in Chemotherapy: Mathematical Modelling for Spatio-temporal Drug Distribution and Model-Based Optimisation. <b>2019</b> , 11,	4
384	Chitosan-Based Drug Delivery Systems. <b>2019</b> , 259-289	1
383	Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells. <b>2019</b> , 2019, 9293560	10

382	Chemotherapeutic Drug Delivery and Quantitative Analysis of Proliferation, Apoptosis, and Migration in a Tissue-Engineered Three-Dimensional Microvessel Model of the Tumor Microenvironment. <b>2019</b> , 5, 633-643	8
381	Time Interval of Two Injections and First-Dose Dependent of Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomal Gambogic Acid: The Contribution of PEG-Specific IgM. <b>2019</b> , 108, 641-651	16
380	Blood Interactions, Pharmacokinetics, and Depth-Dependent Ablation of Rat Mammary Tumors with Photoactivatable, Liposomal Doxorubicin. <b>2019</b> , 18, 592-601	13
379	The availability of drug by liposomal drug delivery : Individual kinetics and tissue distribution of encapsulated and released drug in mice after administration of PEGylated liposomal prednisolone phosphate. <b>2019</b> , 37, 890-901	7
378	Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment. <b>2019</b> , 9, 260-272	30
377	Delivery of Cancer Nanotherapeutics. <b>2019</b> , 163-205	1
376	Nanotechnology Toward Treating Cancer: A Comprehensive Review. <b>2019</b> , 221-256	22
375	Nanoparticles Mediated Gene Knockout Through miRNA Replacement: Recent Progress and Challenges. <b>2019</b> , 469-497	5
374	Oral Nanotherapeutics for Cancer with Innovations in Lipid and Polymeric Nanoformulations. <b>2019</b> , 207-229	
373	Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. <b>2019</b> , 293, 183-192	22
372	Solid State Characterization of Ciprofloxacin Liposome Nanocrystals. <b>2019</b> , 16, 184-194	9
371	The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof-of-Concept Clinical Study. <b>2019</b> , 31, e1803335	68
370	Physiologically Based Pharmacokinetic Modeling of Nanoparticles. <b>2019</b> , 108, 58-72	71
369	Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin. <b>2019</b> , 29, 53-65	12
368	Polymer-drug conjugates as nanomedicine: a review. <b>2020</b> , 69, 990-1014	12
367	Clinical applications of nanomedicine in cancer therapy. <b>2020</b> , 25, 107-125	46
366	Synthesis of $\beta$ -cyclodextrin-PEG-G molecules to delay tumor growth and application of $\beta$ -cyclodextrin-PEG-G aggregates as drug carrier. <b>2020</b> , 229, 115478	6
365	Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. <b>2020</b> , 26, 434-444	36

364	Ligand-Installed Nanocarriers toward Precision Therapy. <b>2020</b> , 32, e1902604	117
363	Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than Doxil. <b>2020</b> , 15, 385-396	15
362	The Benefits of Macromolecular/Supramolecular Approaches in Hydrogen Sulfide Delivery: A Review of Polymeric and Self-Assembled Hydrogen Sulfide Donors. <b>2020</b> , 32, 79-95	20
361	Mathematical modeling of the receptor-mediated endocytosis process of targeted therapeutic agents in drug delivery systems. <b>2020</b> , 79, 300-313	4
360	Critical considerations for targeting colorectal liver metastases with nanotechnology. <b>2020</b> , 12, e1588	10
359	Drug-loaded titanium dioxide nanoparticle coated with tumor targeting polymer as a sonodynamic chemotherapeutic agent for anti-cancer therapy. <b>2020</b> , 24, 102110	35
358	Collaborative assembly of doxorubicin and galactosyl diblock glycopolymers for targeted drug delivery of hepatocellular carcinoma. <b>2020</b> , 8, 189-200	11
357	An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics. <b>2020</b> , 12, 1894-1903	10
356	Indium-111 labelling of liposomal HEGF for radionuclide delivery via ultrasound-induced cavitation. <b>2020</b> , 319, 222-233	3
355	Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer. <b>2020</b> , 85, 353-365	2
354	A glance over doxorubicin based-nanotherapeutics: From proof-of-concept studies to solutions in the market. <b>2020</b> , 317, 347-374	33
353	A mechanistic explanation of the inhibitory role of the protein corona on liposomal gene expression. <b>2020</b> , 1862, 183159	4
352	Synthesis, characterization and in vitro toxicity evaluation of doxorubicin-loaded magnetoliposomes on MCF-7 breast cancer cell line. <b>2020</b> , 55, 101447	9
351	Passive targeting in nanomedicine: fundamental concepts, body interactions, and clinical potential. <b>2020</b> , 37-53	21
350	A pharmacokinetics primer for preclinical nanomedicine research. <b>2020</b> , 109-128	2
349	Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years. <b>2020</b> , 12,	1
348	Stimuli-responsive phospholipid-drug conjugates (PDCs)-based nanovesicles for drug delivery and theranostics. <b>2020</b> , 590, 119920	3
347	Quantitative determination of Cu-liposome accumulation at inflammatory and infectious sites: Potential for future theranostic system. <b>2020</b> , 327, 737-746	4

346	Self-Assembly of Amphiphilic Compounds as a Versatile Tool for Construction of Nanoscale Drug Carriers. <b>2020</b> , 21,	18
345	Covalent Organic Framework Embedded with Magnetic Nanoparticles for MRI and Chemo-Thermotherapy. <b>2020</b> , 142, 18782-18794	37
344	When liposomes met antibodies: Drug delivery and beyond. <b>2020</b> , 154-155, 151-162	18
343	New insights into the activities and toxicities of the old anticancer drug doxorubicin. <b>2021</b> , 288, 6095-6111	38
342	Doxorubicin-loaded composite nanogels for cancer treatment. <b>2020</b> , 328, 171-191	20
341	What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right. <b>2020</b> , 14, 12281-12290	61
340	DNA-Controlled Encapsulation of Small Molecules in Protein Nanoparticles. <b>2020</b> , 142, 17938-17943	4
339	Poly (isopropyl-oxazoline) micelle nanocarrier as dual-responsive prodrug for targeted doxorubicin delivery. <b>2020</b> , 59, 101914	4
338	Polar Lipid Fraction E from and Dipalmitoylphosphatidylcholine Can Form Stable yet Thermo-Sensitive Tetraether/Diester Hybrid Archaeosomes with Controlled Release Capability. <b>2020</b> , 21,	5
337	Enhanced Cancer-targeted Drug Delivery Using Precoated Nanoparticles. <b>2020</b> , 20, 8903-8911	18
336	Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu Gradient Method. <b>2020</b> , 21, 325	1
335	Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity. <b>2020</b> , 12,	33
334	Next-Generation Polymeric Nanomedicines for Oncology: Perspectives and Future Directions. <b>2020</b> , 41, e2000319	8
333	Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis. <b>2020</b> , 48, 300060520944310	2
332	Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology. <b>2020</b> , 18, 1559325820936161	30
331	Nanopharmaceuticals: A focus on their clinical translatability. <b>2020</b> , 578, 119098	31
330	Combined Therapeutic Effects of I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer. <b>2020</b> , 15, 2777-2787	4
329	Sensitization of drug resistant sarcoma tumors by membrane modulation via short chain sphingolipid-containing nanoparticles. <b>2020</b> , 12, 16967-16979	2

328	Engineering long-circulating nanomaterial delivery systems. <b>2020</b> , 66, 131-139	8
327	Designed proteinoid polymers and nanoparticles encapsulating risperidone for enhanced antipsychotic activity. <b>2020</b> , 18, 149	1
326	Enhanced In Vitro Magnetic Cell Targeting of Doxorubicin-Loaded Magnetic Liposomes for Localized Cancer Therapy. <b>2020</b> , 10,	4
325	Synergistic Effects of Pulsed Focused Ultrasound and a Doxorubicin-Loaded Microparticle-Microbubble Complex in a Pancreatic Cancer Xenograft Mouse Model. <b>2020</b> , 46, 3046-3058	1
324	Hyperthermia and Temperature-Sensitive Nanomaterials for Spatiotemporal Drug Delivery to Solid Tumors. <b>2020</b> , 12,	14
323	The Basement Membrane in a 3D Breast Acini Model Modulates Delivery and Anti-Proliferative Effects of Liposomal Anthracyclines. <b>2020</b> , 13,	3
322	Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme. <b>2020</b> , 2, 4498-4509	3
321	Liposomes for Intra-Articular Analgesic Drug Delivery in Orthopedics: State-of-Art and Future Perspectives. Insights from a Systematic Mini-Review of the Literature. <b>2020</b> , 56,	4
320	Photodynamic Priming Modulates Endothelial Cell-Cell Junction Phenotype for Light-activated Remote Control of Drug Delivery. <b>2021</b> , 27,	4
319	Engineering Smart Targeting Nanovesicles and Their Combination with Hydrogels for Controlled Drug Delivery. <b>2020</b> , 12,	31
318	Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. <b>2020</b> , 16, 2959-2979	12
317	Reactive Oxygen Species-Responsive Liposomes via Boronate-Caged Phosphatidylethanolamine. <b>2020</b> , 31, 2220-2230	5
316	Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom. <b>2020</b> , 12,	1
315	A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer. <b>2020</b> , 7, 2002852	2
314	Co-Delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy Against Melanoma Cells. <b>2020</b> , 21, 304	3
313	Nanobowl-Supported Liposomes Improve Drug Loading and Delivery. <b>2020</b> , 20, 4177-4187	41
312	Multi-objective optimization of tumor response to drug release from vasculature-bound nanoparticles. <b>2020</b> , 10, 8294	8
311	Modeling EV Kinetics for Use in Early Cancer Detection. <b>2020</b> , 4, e1900305	10

310	The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan. <b>2020</b> , 2020, 5729389	1
309	Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics. <b>2020</b> , 12,	29
308	Safety Considerations of Cancer Nanomedicine-A Key Step toward Translation. <b>2020</b> , 16, e2000673	16
307	Nanoengineered targeting strategy for cancer immunotherapy. <b>2020</b> , 41, 902-910	6
306	Liposomal Nanotherapy for Treatment of Atherosclerosis. <b>2020</b> , 9, e2000465	10
305	Translational considerations in nanomedicine: The oncology perspective. <b>2020</b> , 158, 140-157	17
304	Synthesis of amino-cosubstituted polyorganophosphazenes and fabrication of their nanoparticles for anticancer drug delivery. <b>2020</b> , 137, 49424	1
303	Development of clinically effective formulations for anticancer applications: why it is so difficult?. <b>2020</b> , 599-723	
302	Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin Formation of the Membrane Attack Complex. <b>2020</b> , 14, 7808-7822	31
301	Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer. <b>2020</b> , 6, eaay1601	63
300	Rapid scale-up and production of active-loaded PEGylated liposomes. <b>2020</b> , 586, 119566	11
299	Liposomes: Advancements and innovation in the manufacturing process. <b>2020</b> , 154-155, 102-122	72
298	Fabrication of 3D-Printed Fish-Gelatin-Based Polymer Hydrogel Patches for Local Delivery of PEGylated Liposomal Doxorubicin. <b>2020</b> , 18,	21
297	A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release. <b>2020</b> , 153, 257-272	7
296	Consensus protocols for animal experimentation and nanomedicine trials at clinical stage in breast cancer. <b>2020</b> , 331-349	1
295	Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies. <b>2020</b> , 163-164, 65-83	95
294	Active matter therapeutics. <b>2020</b> , 31,	27
293	Targeted Nanomedicines: In the Right Route Towards Improved Therapies. <b>2020</b> , 16, 3-4	2

292	Recent advances in the bioanalytical methods of polyethylene glycols and PEGylated pharmaceuticals. <b>2020</b> , 43, 1978-1997	8
291	Hyperthermia and smart drug delivery systems for solid tumor therapy. <b>2020</b> , 163-164, 125-144	62
290	Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs. <b>2020</b> , 106, 301-313	9
289	Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines. <b>2020</b> , 43, 80-99	7
288	Taking advantage of cancer's pH alterations: pH-sensitive nanoparticles. <b>2020</b> , 523-540	
287	Potential of nano-phytochemicals in cervical cancer therapy. <b>2020</b> , 505, 60-72	17
286	The Use of Lactose as an Alternative Coating for Nanoparticles. <b>2020</b> , 109, 1573-1580	5
285	Twenty-five years of polymersomes: lost in translation?. <b>2020</b> , 7, 1297-1309	46
284	Improving the biological activity of fingolimod loaded PHBV nanoparticles by using hydrophobically modified alginate. <b>2020</b> , 46, 318-328	1
283	PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies. <b>2020</b> , 25,	3
282	Suppression of cancer stem cells. <b>2020</b> , 365-398	
281	Doxorubicin-loaded bacterial outer-membrane vesicles exert enhanced anti-tumor efficacy in non-small-cell lung cancer. <b>2020</b> , 10, 1534-1548	36
280	Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity. <b>2020</b> , 7, 50	13
279	Exposure of liposomes containing nanocrystallised ciprofloxacin to digestive media induces solid-state transformation and altered in vitro drug release. <b>2020</b> , 323, 350-360	5
278	New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. <b>2020</b> , 250, 117599	51
277	Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives. <b>2021</b> , 69, 52-68	51
276	Targeted Engineering of Medicinal Chemistry for Cancer Therapy: Recent Advances and Perspectives. <b>2021</b> , 60, 5626-5643	13
275	Zielgerichtete Wirkstoffe für die Krebstherapie: Aktuelle Entwicklungen und Perspektiven. <b>2021</b> , 133, 5686-5705	1

274	Clinical Translation of Self-Assembled Cancer Nanomedicines. <b>2021</b> , 4, 2000159	17
273	Synergistic co-loading of vincristine improved chemotherapeutic potential of pegylated liposomal doxorubicin against triple negative breast cancer and non-small cell lung cancer. <b>2021</b> , 31, 102320	8
272	Preventing and Treating Anthracycline Cardiotoxicity: New Insights. <b>2021</b> , 61, 309-332	18
271	Is Tumor Cell Specificity Distinct from Tumor Selectivity In Vivo?: A Quantitative NIR Molecular Imaging Analysis of Nanoliposome Targeting. <b>2021</b> , 14, 1344-1354	5
270	Evaluation of bovine milk extracellular vesicles for the delivery of locked nucleic acid antisense oligonucleotides. <b>2021</b> , 158, 198-210	12
269	Stimuli-Responsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy. <b>2021</b> , 10, e2001044	11
268	Clinical applications of nanomedicines in lung cancer treatment. <b>2021</b> , 121, 134-142	14
267	Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer. <b>2021</b> , 6, e10188	7
266	Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin. <b>2021</b> , 31, 1-10	7
265	Implications of nanotechnology for the treatment of cancer: Recent advances. <b>2021</b> , 69, 190-199	13
264	Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment. <b>2021</b> , 68, 175-185	13
263	Lipid bubbles combined with low-intensity ultrasound enhance the intratumoral accumulation and antitumor effect of pegylated liposomal doxorubicin. <b>2021</b> , 28, 530-541	4
262	Nanoparticles in medical imaging. <b>2021</b> , 175-210	1
261	Preparation, Characterization, and In Vitro Pharmacodynamics and Pharmacokinetics Evaluation of PEGylated Urolithin A Liposomes. <b>2021</b> , 22, 26	4
260	Regulatory, safety, and toxicological concerns of nanomaterials with their manufacturing issues. <b>2021</b> , 93-115	
259	Nano-pharmacokinetics: biodistribution and toxicology. <b>2021</b> , 117-152	
258	Heparin modulates the cellular uptake of nanomedicines. <b>2021</b> , 9, 1227-1231	2
257	Immune-Targeted Nanomedicine. <b>2021</b> , 294-305	

256	Polysaccharides for Drug Delivery: The Development of Polysaccharide-Based Materials and Glycopolymer to Improve Drug Delivery Applications. <b>2021</b> , 34-50	
255	Hypersensitivity reaction to pegylated liposomal doxorubicin administration for Mullerian carcinoma in Japanese women. <b>2021</b> , 47, 1544-1548	2
254	The ADME Encyclopedia. <b>2021</b> , 1-13	
253	MR-labelled liposomes and focused ultrasound for spatiotemporally controlled drug release in triple negative breast cancers in mice. <b>2021</b> , 5, 125-142	6
252	Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes. <b>2021</b> , 133, 111059	12
251	Recent advances in electrospun allopathic anti-cancerous drug delivery systems. <b>2021</b> , 43, 2864-2867	1
250	Strategies for ligand-installed nanocarriers. <b>2021</b> , 633-655	0
249	In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. <b>2021</b> , 13, 87-105	1
248	Fiber-Reinforced-Phospholipid Vehicle-Based Delivery of l-Ascorbic Acid: Development, Characterization, ADMET Profiling, and Efficacy by a Randomized, Single-Dose, Crossover Oral Bioavailability Study. <b>2021</b> , 6, 5560-5568	1
247	Efficacy of pH-Sensitive Nanomedicines in Tumors with Different c-MYC Expression Depends on the Intratumoral Activation Profile. <b>2021</b> , 15, 5545-5559	5
246	Targeted drug delivery strategies for precision medicines.. <b>2021</b> , 6, 351-370	86
245	Advances in the Formulation and Assembly of Non-Cationic Lipid Nanoparticles for the Medical Application of Gene Therapeutics. <b>2021</b> , 11,	2
244	How far have we explored fungi to fight cancer?. <b>2021</b> ,	41
243	Rational nanocarrier design towards the clinical translation of cancer nanotherapy. <b>2021</b> ,	4
242	Covalently Functionalized Carbon Nano-Onions Integrated Gelatin Methacryloyl Nanocomposite Hydrogel Containing $\beta$ Cyclodextrin as Drug Carrier for High-Performance pH-Triggered Drug Release. <b>2021</b> , 14,	13
241	Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety. <b>2021</b> , 11, 597453	1
240	Cancer Therapy Using a Targeted Magnetoliposomes Encapsulated Doxorubicin Assisted Ultrasound. 1-8	2
239	Role of stealth lipids in nanomedicine-based drug carriers. <b>2021</b> , 235, 105036	3

238	Specificity of pharmacokinetic modeling of nanomedicines. <b>2021</b> , 26, 2259-2268	0
237	New Insights and Novel Therapeutic Potentials for Macrophages in Myocardial Infarction. <b>2021</b> , 44, 1696-1712	9
236	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. <b>2021</b> , 50, 743-779	8
235	Optimized Photoactivatable Lipid Nanoparticles Enable Red Light Triggered Drug Release. <b>2021</b> , 17, e2008198	9
234	Characterization techniques: The stepping stone to liposome lyophilized product development. <b>2021</b> , 601, 120519	0
233	A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models. <b>2021</b> , 38, 1093-1106	3
232	Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers. <b>2021</b> , 112, 2493-2503	5
231	Effect of the ammonium salt anion on the structure of doxorubicin complex and PEGylated liposomal doxorubicin nanodrugs. <b>2021</b> , 1865, 129849	2
230	Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy. <b>2021</b> , 16, 95	28
229	Dual-Targeting and Stimuli-Triggered Liposomal Drug Delivery in Cancer Treatment. <b>2021</b> , 4, 1028-1049	5
228	Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization. <b>2021</b> , e2100639	23
227	A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer. <b>2021</b> , 26, 1977-1985	0
226	Formulation and In Vitro Characterization of PLGA/PLGA-PEG Nanoparticles Loaded with Murine Granulocyte-Macrophage Colony-Stimulating Factor. <b>2021</b> , 22, 191	1
225	Multistage Adaptive Nanoparticle Overcomes Biological Barriers for Effective Chemotherapy. <b>2021</b> , 17, e2100578	6
224	Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer. <b>2021</b> , 13,	3
223	Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine. <b>2021</b> , 38, 1209-1219	5
222	Nanomedicine at the crossroads - A quick guide for IVIVC. <b>2021</b> , 179, 113829	7
221	HPLC-DAD-CAD-based approach for the simultaneous analysis of hydrophobic drugs and lipid compounds in liposomes and for cyclodextrin/drug inclusion complexes. <b>2021</b> , 201, 114120	1

220	Thrombotic microangiopathy in oncology - a review. <b>2021</b> , 14, 101081	4
219	Insight into chitosan derived nanotherapeutics for anticancer drug delivery and imaging. <b>2021</b> , 154, 110540	3
218	Nanotechnology-based approaches for emerging and re-emerging viruses: Special emphasis on COVID-19. <b>2021</b> , 156, 104908	8
217	Insight Into the Molecular Mechanism of Podophyllotoxin Derivatives as Anticancer Drugs. <b>2021</b> , 9, 709075	5
216	Development of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells. <b>2021</b> , 16, 5437-5449	3
215	The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. <b>2021</b> , 11,	37
214	Challenges towards Targeted Drug Delivery in Cancer Nanomedicines. <b>2021</b> , 9, 1527	4
213	Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. <b>2021</b> , 275, 120910	14
212	Iron Oxide Nanoparticles Synthesized Via Green Tea Extract for Doxorubicin Delivery. <b>2021</b> , 17, 646-657	1
211	An exploratory first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2- and 1-week interval in patients with metastatic castration resistant prostate cancer. <b>2021</b> , 9, e00845	0
210	Novel pegylated liposomal formulation of docetaxel with 3-n-pentadecylphenol derivative for cancer therapy. <b>2021</b> , 163, 105838	4
209	Nanoplatfrom-based natural products co-delivery system to surmount cancer multidrug-resistant. <b>2021</b> , 336, 396-409	2
208	Iron oxide Nanoparticles in Anticancer Drug Delivery and Imaging Diagnostics. <b>2021</b> , 151-163	
207	Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers. <b>2021</b> , 178, 113992	5
206	Liposomes: Ideal drug delivery systems in breast cancer. <b>2021</b> ,	1
205	Liposome composition in drug delivery design, synthesis, characterization, and clinical application. <b>2021</b> , 176, 113851	65
204	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <b>2021</b> , 13,	2
203	Using Parallel Coordinates in Optimization of Nano-Particle Drug Delivery. <b>2022</b> , 144,	0

202	Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. <b>2021</b> , 176, 113891	17
201	Studies on cancer cell death through delivery of dopamine as anti-cancer drug by a newly functionalized cobalt ferrite nano-carrier. <b>2021</b> , 627, 127202	2
200	Cur-loaded magnetic ZnFe <sub>2</sub> O <sub>4</sub> @mZnO-Ox-p-g-C <sub>3</sub> N <sub>4</sub> composites as dual pH- and ultrasound responsive nano-carriers for controlled and targeted cancer chemotherapy. <b>2021</b> , 271, 124863	6
199	Dynamic contrast enhanced magnetic resonance imaging: A review of its application in the assessment of placental function. <b>2021</b> , 114, 90-99	4
198	Carbon nanotubes as an emerging nanocarrier for the delivery of doxorubicin for improved chemotherapy. <b>2021</b> , 208, 112044	20
197	Sequential administration of PEG-Span 80 niosome enhances anti-tumor effect of doxorubicin-containing PEG liposome. <b>2021</b> , 169, 20-28	4
196	Nanotargeting to the kidney. <b>2022</b> , 439-449	
195	Nanomaterials: Synthesis, physicochemical characterization, and biopharmaceutical applications. <b>2021</b> , 33-70	
194	Metal-Organic Frameworks as Delivery Systems of Small Drugs and Biological Gases. <b>2021</b> , 349-378	1
193	The effect of PEGylation on the efficacy and uptake of an immunostimulatory nanoparticle in the tumor immune microenvironment. <b>2021</b> , 3, 4961-4972	2
192	Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy. <b>2021</b> , 1295, 77-95	5
191	Preparation and Evaluation of Integrin Receptor-Mediated Targeting Drug Liposomes. <b>2021</b> , 213-237	
190	An exosome-mimicking membrane hybrid nanoplatfom for targeted treatment toward Kras-mutant pancreatic carcinoma. <b>2021</b> , 9, 5599-5611	2
189	Polymer Therapeutics for Cancer: Current Status and Future Challenges. 1-65	105
188	Use of Radiolabeled Liposomes for Tumor Imaging. <b>2008</b> , 211-236	1
187	Liposomes and Polymers in Folate-Targeted Cancer Therapeutics. <b>2011</b> , 217-247	1
186	Nanomedicine in Cancer Diagnosis and Therapy: Converging Medical Technologies Impacting Healthcare. <b>2014</b> , 365-384	1
185	Integrated platform for brain imaging and drug delivery across the blood-brain barrier. <b>2011</b> , 686, 465-81	17

184	Nanotechnology: A Potential Tool in Exploring Herbal Benefits. <b>2020</b> , 27-46	3
183	Ultrasound mediated localized drug delivery. <b>2012</b> , 733, 145-53	12
182	Anthracyclines. <b>2005</b> , 19-33	1
181	Topoisomerase II inhibitors. <b>2005</b> , 22, 101-21	23
180	Radiolabeling of Liposomes for Scintigraphic Imaging. <b>2006</b> , 169-185	2
179	Anthracyclines. <b>2005</b> ,	1
178	Biomaterial-Based Particulate Drug Carriers. <b>2012</b> , 1-20	1
177	Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids. <b>2011</b> , 6, e25721	49
176	Quantitative Analysis of the Enhanced Permeation and Retention (EPR) Effect. <b>2015</b> , 10, e0123461	68
175	Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. <b>2009</b> , 26, 523-80	588
174	Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance.. <b>2021</b> , 4, 192-207	1
173	Targeted therapy using nanotechnology: focus on cancer. <b>2014</b> , 9, 467-83	239
172	Epigenetic Metalloenzymes. <b>2019</b> , 26, 2748-2785	7
171	Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies. <b>2020</b> , 20, 2762-2776	3
170	Membrane Derived Vesicles as Biomimetic Carriers for Targeted Drug Delivery System. <b>2020</b> , 20, 2472-2492	5
169	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. <b>2015</b> , 19, 1-480	20
168	Safe Nanoparticles: Are We There Yet?. <b>2020</b> , 22,	48
167	Small Peptide-Doxorubicin Co-Assembly for Synergistic Cancer Therapy. <b>2020</b> , 25,	2

166	Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer. <b>2016</b> , 22, 3758-68	11
165	Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study. <b>2020</b> , 31, e15	2
164	Trastuzumab-Doxorubicin Conjugate Provides Enhanced Anti-Cancer Potency and Reduced Cardiotoxicity. <b>2013</b> , 04, 308-322	5
163	Recent Advances in Lipid-Based Nanoformulations for Breast Cancer Theranostics. <b>2021</b> , 175-200	0
162	Nano-scale delivery: A comprehensive review of nano-structured devices, preparative techniques, site-specificity designs, biomedical applications, commercial products, and references to safety, cellular uptake, and organ toxicity. <b>2021</b> , 10, 1493-1559	5
161	Nanoliposomes as drug delivery systems: safety concerns. <b>2021</b> , 1-13	4
160	Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin. <b>2021</b> , 14,	1
159	Multifunctional Gd-CuS loaded UCST polymeric micelles for MR/PA imaging-guided chemo-photothermal tumor treatment. 1	2
158	High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study. <b>2021</b> , 22, 63	1
157	Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy. <b>2021</b> , 21, 1385-1398	4
156	Incorporation of Poly(Ethylene Glycol )Lipid into Lipoplexes. <b>2006</b> , 273-292	
155	Nano-Carriers of Drugs and Genes for the Treatment of Restenosis. <b>2007</b> , 235-269	
154	Long-Circulating Liposomes with Attached Diagnostic Moieties: Application for Gamma and MR Imaging. <b>2008</b> , 431-456	
153	Pegylated Liposome Delivery of Chemotherapeutic Agents. <b>2008</b> , 227-262	
152	The Use of Chemotherapy in Elderly Cancer Patients: Dose Adjusting, Drug Interactions, and Polypharmacy. <b>2010</b> , 315-330	
151	Biomedical Applications I. <b>2011</b> , 23-45	
150	[Liposome formulations of combretastatin A4 and 4-arylcoumarin analog prodrugs: antitumor effect in the mouse model of breast cancer]. <b>2012</b> , 58, 326-38	1
149	Introduction. <b>2013</b> , 1-5	

148	Resistance to Castration [Resistance to Drugs. <b>2013</b> , 127-142	
147	Polymer- and Lipid-Based Systems for Parenteral Drug Delivery. <b>2013</b> , 47-60	0
146	Emerging Potential of Nanoparticles for the Treatment of Solid Tumors and Metastasis. <b>2013</b> , 1-28	
145	Strategies for VirusEnzyme Coupling. <b>2015</b> , 65-124	
144	Drug Delivery: Tumor-Targeted Systems. 2965-2978	
143	DESIGN AND EVALUATION OF STEALTH LIPOSOMES ENCAPSULATING VINOURELBINE TARTARATE. <b>2016</b> , 53, 17-21	
142	Chapter 10 Role of UV-Vis Radiations in Analysis of Polymer Systems for Drug Delivery Applications. <b>2017</b> , 159-174	
141	The anticancer activity and immune modulating properties of combinatorial ensemble complementary (antisense) microRNA (FRNA) in combination with the immunomodulator - glycoprotein lectin from B. subtilis B-7025.	
140	Chapter 8: Lipid Vesicles for Skin Delivery: Evolution from First Generation. <b>2017</b> , 281-322	1
139	Preparation and Evaluation of Integrin Receptor-Mediated Targeting Drug Liposomes. <b>2018</b> , 1-25	
138	Introduction. <b>2018</b> , 1-14	
137	CHAPTER 5. Radiolabelling Liposomal Nanomedicines for PET Imaging. <b>2018</b> , 123-136	
136	Anthracyclines. <b>2018</b> , 5, 1	
135	Liposomal Nanocarriers Designed for Sub-Endothelial Matrix Targeting under Vascular Flow Conditions. <b>2021</b> , 13,	1
134	Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface. <b>2021</b> , 49, 2253-2269	1
133	Current Understandings and Clinical Translation of Nanomedicines for Breast Cancer Therapy. <b>2021</b> , 180, 114034	5
132	Nanotechnology Assisted Targeted Drug Delivery for Bone Disorders: Potentials and Clinical Perspectives. <b>2020</b> , 20, 2801-2819	3
131	The evaluation of lymph node cell proliferation response by liposomes loaded with major histocompatibility complex class II binding aquaporin 4 antigen peptide. <b>2021</b> , 85, 537-544	1

130	Response of isolated buccal epithelium cells on the combined action of anti-tumor antibiotic doxorubicin and magnetic field. <b>2021</b> , 14-23	
129	Lipid-Based Tumor-targeted Systems. <b>2020</b> , 293-336	
128	Toxicology and Safety of Nanoparticles in Drug Delivery System. <b>2021</b> , 329-348	
127	Drug transport to brain with targeted liposomes. <b>2005</b> , 2, 99-107	
126	Direct quantitation of free, encapsulated, total doxorubicin and doxorubicinol in stabilized frozen human plasma to support a BE study of liposomal doxorubicin. <b>2020</b> , 189, 113388	0
125	Tumor targeting using liposomal antineoplastic drugs. <b>2008</b> , 3, 21-9	40
124	Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. <b>2007</b> , 2, 567-83	128
123	New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. <b>2009</b> , 1, 1-18	1
122	Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines. <b>2016</b> , 80, 209-16	8
121	PSMB5 plays a dual role in cancer development and immunosuppression. <b>2017</b> , 7, 2103-2120	22
120	Repositioning antipsychotic fluphenazine hydrochloride for treating triple negative breast cancer with brain metastases and lung metastases. <b>2019</b> , 9, 459-478	9
119	Polymer-Lipid Hybrid Materials. <b>2021</b> , 121, 13996-14030	3
118	Magnetically induced controlled release from glucose-modified liposomes loaded with Fe <sub>3</sub> O <sub>4</sub> nanoparticles. <b>2021</b> , 23, 1	1
117	Surface-engineered liposomal particles of calcium ascorbate with fenugreek galactomannan enhanced the oral bioavailability of ascorbic acid: a randomized, double-blinded, 3-sequence, crossover study.. <b>2021</b> , 11, 38161-38171	1
116	Combating complement's deleterious effects on nanomedicine by conjugating complement regulatory proteins to nanoparticles.. <b>2021</b> , e2107070	2
115	Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial.. <b>2021</b> , 341, 548-554	0
114	Biological protein mediated ferroptotic tumor nanotherapeutics. <b>2021</b> , 9, 9262-9284	0
113	The in vivo pharmacokinetics of block copolymers containing polyethylene glycol used in nanocarrier drug delivery systems.. <b>2022</b> ,	1

112	Application of Nanoemulsion in Cancer Treatment. <b>2022</b> , 237-258	
111	Liposomal PHD2 Inhibitors and the Enhanced Efficacy in Stabilizing HIF-1 $\beta$ <b>2022</b> , 12,	
110	Revisiting the outstanding questions in cancer nanomedicine with a future outlook. <b>2022</b> , 4, 634-653	0
109	The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart.. <b>2022</b> , 13,	6
108	Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis.. <b>2022</b> , 343, 175-175	1
107	Doxorubicin-Loaded UiO-66/BiS Nanocomposite-Enhanced Synergistic Transarterial Chemoembolization and Photothermal Therapy against Hepatocellular Carcinoma.. <b>2022</b> ,	1
106	Preclinical Animal Models for the Experimental Design of Pharmacokinetic Studies with Nanoparticulate Drug Delivery Systems. <b>2022</b> , 79-100	
105	Nanocarriers Call the Last Shot in the Treatment of Brain Cancers.. <b>2022</b> , 21, 15330338221080974	0
104	Nanoparticle Pharmacokinetic Profiling In Vivo Using Magnetic Resonance Imaging. <b>2022</b> , 399-416	
103	The Emerging Role of Ultrasonic Nanotechnology for Diagnosing and Treatment of Diseases.. <b>2022</b> , 9, 814986	1
102	Recent Advancements of Stimuli-Responsive Targeted Liposomal Formulations for Cancer Drug Delivery.. <b>2022</b> ,	0
101	Increased Targeting Area in Tumors by Dual-Ligand Modification of Liposomes with RGD and TAT Peptides.. <b>2022</b> , 14,	2
100	Imidazole-Based pH-Sensitive Convertible Liposomes for Anticancer Drug Delivery.. <b>2022</b> , 15,	2
99	Recent advances of nanodrug delivery system in the treatment of hematologic malignancies.. <b>2022</b> ,	0
98	Efficacy and Safety of Nanoadministration in the Treatment of Non-Small-Cell Lung Cancer Is Good to Some Extent: A Systematic Review and Meta-Analysis.. <b>2022</b> , 2022, 9017198	
97	Polymer-Modified Liposomes for Drug Delivery: From Fundamentals to Applications.. <b>2022</b> , 14,	5
96	Re-directing nanomedicines to the spleen: A potential technology for peripheral immunomodulation.. <b>2022</b> ,	1
95	Nose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties.. <b>2022</b> ,	3

94	Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy.. <b>2022,</b>	3
93	The Effect of Repeat Administration of Lipoplexes on Gene Delivery, Biodistribution, and Cytokine Response in Immunocompetent Tumor-bearing Mice.. <b>2021,</b>	1
92	Stress Granules in the Anti-Cancer Medications Mechanism of Action: A Systematic Scoping Review.. <b>2021, 11, 797549</b>	0
91	PEGylated Nanoparticles as a Versatile Drug Delivery System. <b>2022, 309-341</b>	1
90	Enhanced Therapeutic Effect of Liposomal Doxorubicin Bio-Orthogonal Chemical Reactions in Tumors.. <b>2022,</b>	0
89	Imaged-guided focused ultrasound in combination with various formulations of doxorubicin for the treatment of diffuse intrinsic pontine glioma. <b>2022, 7,</b>	1
88	Image_1.tif. <b>2019,</b>	
87	Image_2.tif. <b>2019,</b>	
86	Image_3.tif. <b>2019,</b>	
85	Image_4.tif. <b>2019,</b>	
84	Image_5.tif. <b>2019,</b>	
83	Image_6.tif. <b>2019,</b>	
82	Image_7.tif. <b>2019,</b>	
81	DataSheet_1.pdf. <b>2019,</b>	
80	Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate.. <b>2022, 120574</b>	5
79	Liposomes in the Targeted Gene Therapy of Cancer: A Critical Review.. <b>2022,</b>	
78	A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human.. <b>2022, 1</b>	0
77	One-Pot, One-Step Synthesis of Drug-Loaded Magnetic Multimicelle Aggregates.. <b>2022,</b>	

76	Macrophage Membrane Biomimetic Drug Delivery System: for Inflammation Targeted Therapy.. <b>2022</b> , 1-47	0
75	Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?.	19
74	pH-Sensitive Liposomes for Enhanced Cellular Uptake and Cytotoxicity of Daunorubicin in Melanoma (B16-BL6) Cell Lines. <b>2022</b> , 14, 1128	2
73	Nanoparticle-based medicines in clinical cancer therapy. <b>2022</b> , 45, 101512	7
72	Armamentarium in drug delivery for colorectal cancer. <b>2022</b> ,	
71	Liposomal siRNA Delivery in Papillary Thyroid Carcinoma Cells. <b>2022</b> , 121-133	
70	Pharmaceutical Nanocarriers: Nanotoxicology. <b>2022</b> , 840-853	
69	Targeted In Vivo Loading of Red Blood Cells Markedly Prolongs Nanocarrier Circulation.	1
68	Liposomal Formulations of a New Zinc(II) Complex Exhibiting High Therapeutic Potential in a Murine Colon Cancer Model. <b>2022</b> , 23, 6728	2
67	Combined Second Harmonic Generation and Fluorescence Analyses of the Structures and Dynamics of Molecules on Lipids Using Dual-Probes: A Review. <b>2022</b> , 27, 3778	
66	Improved survival rate and minimal side effects of doxorubicin for lung metastasis using engineered discoidal polymeric particles.	
65	Thermosensitive liposomes: A promising step towards localised chemotherapy.	1
64	The role of lipid components in lipid nanoparticles for vaccines and gene therapy. <b>2022</b> , 188, 114416	11
63	How docetaxel entrapment, vesicle size, zeta potential and stability change with liposome composition? A formulation screening study. <b>2022</b> , 177, 106267	0
62	Identifying cell receptors for the nanoparticle protein corona using genome screens. <b>2022</b> , 18, 1023-1031	2
61	Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer. <b>2022</b> , 15,	0
60	Industrialization? eye view on theranostic nanomedicine. 10,	
59	Temperature-sensitive polymers to promote heat-triggered drug release from liposomes: towards bypassing EPR. <b>2022</b> , 114503	0

58	Engineering nanosystems to overcome barriers to cancer diagnosis and treatment. <b>2022</b> , 189, 114482	2
57	Enhanced delivery to brain using sonosensitive liposome and microbubble with focused ultrasound. <b>2022</b> , 141, 213102	3
56	Stealth nanoparticles in oncology: Facing the PEG dilemma. <b>2022</b> , 351, 22-36	2
55	Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers. <b>2022</b> , 190, 114525	1
54	Functionalized liposomes: a nanovesicular system. <b>2022</b> , 83-101	0
53	Insights on Development Aspects of Polymeric Nanocarriers: The Translation from Bench to Clinic. <b>2022</b> , 14, 3545	4
52	Natural Products and Drug Discovery.	0
51	Placental Nanoparticle Uptake-On-a-Chip: The Impact of Trophoblast Syncytialization and Shear Stress.	0
50	Capillary electrophoresis-mass spectrometry in pharmaceutical and biomedical analyses. <b>2022</b> , 221, 115059	0
49	Pharmacokinetics of intact lipid nanocapsules using new quantitative FRET technique. <b>2022</b> , 351, 681-691	0
48	Microfluidic chip interfacing microdialysis and mass spectrometry for in vivo monitoring of nanomedicine pharmacokinetics in real time. <b>2022</b> , 1683, 463520	0
47	Synthesis and Biological Use of Nanomaterials. <b>2022</b> , 793-858	0
46	Pegylated liposomal doxorubicin combined with ifosfamide for treating advanced or metastatic soft tissue sarcoma: a prospective, single-arm phase II study.	1
45	Intracellular and extracellular enzymatic responsive micelle for intelligent therapy of cancer.	1
44	Doxorubicin-Loaded Polymeric Micelles Conjugated with CKR- and EVQ-FLT3 Peptides for Cytotoxicity in Leukemic Stem Cells. <b>2022</b> , 14, 2115	0
43	Insights into the mapping of green synthesis conditions for ZnO nanoparticles and their toxicokinetics.	0
42	Inhibition of colorectal cancer tumorigenesis by ursolic acid and doxorubicin is mediated by targeting the Akt signaling pathway and activating the Hippo signaling pathway. <b>2022</b> , 27,	0
41	Phosphate-Trapping Liposomes for Long-Term Management of Hyperphosphatemia. <b>2022</b> , 15, 7779	0

40	Microfluidic vortex focusing for high throughput synthesis of size-tunable liposomes. <b>2022</b> , 13,	0
39	Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors. <b>2022</b> , 100917	1
38	Delivery of Corn-Derived Nanoparticles with Anticancer Activity to Tumor Tissues by Modification with Polyethylene Glycol for Cancer Therapy.	0
37	The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives. <b>2022</b> , 191, 114614	2
36	Folded, undulating, and fibrous doxorubicin sulfate crystals in liposomes. <b>2022</b> , 102631	0
35	Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma. <b>2022</b> , 1-10	0
34	Injectable anti-cancer drug loaded silk-based hydrogel for the prevention of cancer recurrence and post-lumpectomy tissue regeneration aiding triple-negative breast cancer therapy. <b>2023</b> , 145, 213224	0
33	Understanding the Stealth Properties of PEGylated lipids: A Mini-Review. <b>2020</b> , 1, 1-20	2
32	A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx $\square$ in advanced breast cancer. 12,	0
31	Trends in Drug Delivery Systems for Natural Bioactive Molecules to Treat Health Disorders: The Importance of Nano-Liposomes. <b>2022</b> , 14, 2808	0
30	Development of Novel Lipid-Based Formulations for Water-Soluble Vitamin C versus Fat-Soluble Vitamin D3. <b>2022</b> , 9, 819	1
29	Engineering Lipid Spherulites for the Sustained Release of Highly Dosed Small Hydrophilic Compounds. 2202249	0
28	Nanoprobe Based on Biominerals in Protein Corona for Dual-Modality MR Imaging and Therapy of Tumors.	0
27	Drug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan. <b>2022</b> ,	0
26	Interplay of p53 and XIAP protein dynamics orchestrates cell fate in response to chemotherapy.	0
25	Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition. <b>2023</b> ,	0
24	A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma.	0
23	Gliadin Nanoparticles Containing Doxorubicin Hydrochloride: Characterization and Cytotoxicity. <b>2023</b> , 15, 180	0

- 22 Aptamer-functionalized liposomes for targeted cancer therapy. **2023**, 141-172 ○
- 21 Tumor vascular heterogeneity and the impact of subtumoral nanoemulsion biodistribution. **2022**, 17, 2073-2088 ○
- 20 The development of highly dense highly protected surfactant ionizable lipid RNA loaded nanoparticles. 14, ○
- 19 An IgG-hitchhiking approach for rapid tumor accumulation and clearance of photosensitizers. **2023**, 356, 242-255 ○
- 18 An Magnetic-Targeting Nano-Diagnosis and Treatment Platform for TNBC. Volume 15, 101-119 ○
- 17 Biodegradable porous polymeric drug as a drug delivery system: alleviation of doxorubicin-induced cardiotoxicity via passive targeted release. **2023**, 13, 5444-5456 ○
- 16 Enhancing Anti-Tumorigenic Efficacy of Eugenol in Human Colon Cancer Cells Using Enzyme-Responsive Nanoparticles. **2023**, 15, 1145 ○
- 15 PEGylated liposomes enhance the effect of cytotoxic drug: A review. **2023**, 9, e13823 ○
- 14 Delivering on the promise of protein degraders. ○
- 13 Drug Discovery from Natural Sources. **2023**, 9, 67-89 ○
- 12 A Sojourn on Liposomal Delivery System: Recent Advances and Future Prospects. **2023**, 21, 48-64 ○
- 11 Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case-control study. ○
- 10 Pegylated liposomal doxorubicin (Duomeisu<sup>®</sup>) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study. ○
- 9 Doxorubicin-loaded liposomes surface engineered with the matrix metalloproteinase-2 cleavable polyethylene glycol conjugate for cancer therapy. **2023**, 14, ○
- 8 Potential Approaches for Delivery of Surface Decorated Nano-carriers in the Management of Carcinoma. **2023**, 64-105 ○
- 7 Cancer Drug Products Containing Nano-materials: Key Regulatory Issues. **2023**, 349-381 ○
- 6 Recent Preclinical and Clinical Progress in Liposomal Doxorubicin. **2023**, 15, 893 ○
- 5 Probing emergence of biomolecular coronas around drug-loaded liposomal nanoparticles in the solution by using nanoparticle tracking analysis. ○

- 4 Effects of PEG-Linker Chain Length of Folate-Linked Liposomal Formulations on Targeting Ability and Antitumor Activity of Encapsulated Drug. Volume 18, 1615-1630 ○
- 3 Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function. **2023**, 197, 114828 ○
- 2 3D dynamic cultures of HGSOc organoids to model innovative and standard therapies. 11, ○
- 1 Siglec-6 mediates the uptake of extracellular vesicles through a noncanonical glycolipid binding pocket. **2023**, 14, ○